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ABSTRACT 
 
ADAM DAVID GRACZ: THE ROLE OF SRY-BOX (SOX) TRANSCRIPTION 
FACTORS IN EPITHELIAL STEM CELL BIOLOGY OF THE GASTROINTESTINAL 
TRACT 
 
(Under the direction of: Scott T. Magness, Ph.D. and P. Kay Lund, Ph.D.) 
 
 
 Stem cell biology, though a well-established concept in the scientific zeitgeist, is 
only beginning to emerge as an independent field of study. An understanding of basic 
stem cell biology and its translation into clinically applicable therapies holds the potential 
to direct a paradigm shift in modern medical practice. However, in order to realize this 
potential, the scientific community must first understand the genetic and molecular 
mechanisms by which cells acquire and maintain ‘stemness’, specifically, multipotency 
and the ability to self-renew. Studying the transcriptional machinery that controls these 
properties could lead to a greater understanding of stem cells as a component of 
physiology as a whole. Due to its critical importance to homeostasis, the gastrointestinal 
tract is an attractive system for the study of stem cell biology. Sox factors, a group of 
transcription factors that have previously been associated with embryonic and neural 
stem cells, are rapidly emerging as central to maintaining ‘stemness’ in the 
gastrointestinal tract as well. This work reviews the known role of Sox factors in the 
gastrointestinal epithelium and describes our novel findings regarding Sox9 as a marker 
of stem cells in the adult intestinal epithelium.   
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CHAPTER 1 
 
SCOPE OF WORK 
 
 The work presented in this thesis consists largely of two peer-reviewed and 
published manuscripts. The first, presented in Chapter 2, is a comprehensive review of 
the Sox family of transcription factors and their role in the epithelial tissues of the 
gastrointestinal tract. Chapter 3 focuses on original research into specific properties of 
Sox9 in the intestinal epithelium.  
 We chose to pursue investigation of Sox factors in the gastrointestinal tract due to 
their generally accepted function as ubiquitous components of stem cell specific 
molecular signaling, as well as their critical role in maintaining stemness and regulating 
differentiation. Our work identified and validated that Sox9 is an intestinal epithelial stem 
cell (IESC) biomarker. In addition to this major finding, the work presented here 
establishes critical techniques and reagents for the isolation and in vitro study of IESCs, 
and lays the groundwork for mechanistic study of Sox factors in IESCs and progenitors.
 CHAPTER 2 
 
SRY-BOX (SOX) TRANSCRIPTION FACTORS IN GASTROINTESTINAL 
PHYSIOLOGY AND DISEASE 
 
ADAM D GRACZ AND SCOTT T MAGNESS 
 
INTRODUCTION 
Contemporary biomolecular research promises to advance gastroenterology in the 
21st century by providing clinicians and researchers with a growing understanding of the 
molecular mechanisms that underlie both normal physiology and disease of the 
gastrointestinal tract. As the basic and clinical research communities grow closer to 
bridging the gap between bench and bedside, it is apparent that an understanding of 
cellular maintenance and tissue repair mechanisms is central to achieving this goal. Sox 
factors are a family of structurally related transcription factors that are emerging as 
regulators of transcriptional activity with potent effects on cellular phenotypes. This 
review will focus on the current understanding of the role of Sox factors in normal 
cellular maintenance and differentiation, as well as in disease states of the endodermally 
derived tissues of the gastrointestinal tract.  
The gastrointestinal tract, which includes the esophagus, stomach, and small and 
large intestine, is constantly exposed to microbes, chemical toxins or mutagens, varying 
pH, and physical injury to the epithelial barrier. The consequences of compromising the 
epithelial barrier of the gastrointestinal tract are leakage of bacteria into the surrounding 
vasculature, leading to sepsis; or leakage of acid into the underlying mesenchyme 
resulting in ulcers and chronic inflammation. Therefore, tissue renewal driven by
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epithelial stem cells is critical to maintaining constant integrity of epithelial barriers and 
ultimately the survival of the organism.  
In addition to maintaining basal function, tissue-specific stem cells are capable of 
responding to injury, damage, or even large-scale loss of tissue to attempt repair. For 
example, intestinal epithelial stem cells undergo expansion and drive massive tissue 
remodeling following ileo-cecal resection (32). However, stem cell populations do not 
always respond equally to damage. Following pancreatectomy, ductal cell populations of 
the rat pancreas are able to regenerate a large portion of the organ’s original mass, but in 
the case of type I diabetes, there are no regenerative processes that replace destroyed β-
islet cells (16). Further complicating the understanding of stem cell mediated 
regeneration is the observation that conventional animal models do not always exhibit 
responses that translate to human biology. For instance, recent findings indicate that β-
islet cell regeneration does not occur following pancreatectomy in adult human patients, 
as previously observed in rats (16, 86). Aberrant proliferation of tissue-specific stem cells 
is implicated in a wide range of common diseases throughout the gastrointestinal tract, 
including diabetes, cirrhosis, and gastrointestinal cancers (82, 84, 117, 159).  The 
differential abilities of stem cell pools to respond to regenerative stimuli point to intrinsic 
genetic components that influence the stemness of the cell and are capable of reacting to 
extrinsic cues.    
Attempts to expand on the nascent understanding of stem cell maintenance and 
differentiation in the gastrointestinal tract has led to the identification of several gene 
families implicated in the growth and expansion of multipotent stem cell populations. 
Among these families is a group of genes known as Sox (Sry box-containing) 
transcription factors. Founding members of the Sox family were first described in terms 
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of their role in establishing sexual dimorphism in development (46, 70, 118). Shortly 
thereafter, Sox factors were identified in adult neural cell populations where they were 
shown to have powerful roles in maintaining tissue-specific stem cell populations within 
the nervous system (27, 118, 137).   
A common theme in recent studies is that Sox-factors possess a potent capacity to 
direct or influence ’stemness’, or a cell’s ability to meet the established stem cell criteria 
of multipotency and self-renewal. Landmark studies demonstrated that Sox2, along with 
three other transcription factors, possessed the ability to reprogram differentiated adult 
cells to a state of pluripotency resembling that seen in embryonic stem cells (129, 130). 
Taken with the cell-specific expression patterns and redundant function of Sox factors, 
the demonstrated ability of Sox2 to regulate cellular potency suggests that Sox factors 
might play a role in maintaining ‘stemness’ in cells of the gastrointestinal tract.  
 
SOX FACTORS: VERSATILE REGULATORS OF TRANSCRIPTIONAL 
ACTIVITY  
There are currently thirty described Sox factors in mammals. The first Sox gene 
characterized was Sry (sex-determining region Y). Sry was identified as the previously 
reported testis-determining factor, TDF, in sex-reversed human XX males and XY 
females (118). Sox factors represent a family of genes within the high mobility group 
(HMG) superfamily, demonstrating homology in their 79 amino acid HMG-box DNA-
binding domain motifs (46, 118, 122). All Sox factors exhibit a conserved HMG domain 
motif of RFMNAF, which distinguishes them from other HMG-box genes (14). 
However, it has been observed that all Sox factors with the exception of Sry have an 
extended motif homology of RFMNAFMVW and it has been suggested that this 
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homology sequence be used for classification of Sox factors (14). The HMG-box has the 
capacity to bind both DNA consensus elements and other transcriptional regulators, such 
as POU-domain proteins, to modulate transcriptional activity (5, 157). All Sox factors 
studied to date demonstrate the ability to bind a DNA consensus sequence of 
(A/T)(A/T)CAA(A/T)G, allowing these factors to sometimes exhibit functionally 
redundant roles (27, 28, 34, 42, 50, 53, 138). Phylogenic analysis of Sox factor HMG-box 
sequence and protein structure has identified similarities between different Sox genes that 
has resulted in the classification of Sox factors into subgroups A-J (14).  
Sox factors share a striking ability to affect structural changes in DNA. Sox factors 
have been shown to bind the minor groove of the DNA helix, resulting in a significant 
degree of DNA bending not elicited by other members of the HMG superfamily that bind 
to specific DNA sequences (37, 42). The participation of Sox factors in regulating a 
conformational change in DNA suggests that these factors may possess powerful 
transcriptional modulating roles that go beyond the function of site-specific 
transcriptional activation and implies an effect on larger-order chromatin structure (37).  
Observations regarding the architectural effect of Sox factors on DNA highlight 
the significance of this property. Early studies on the role of Sry in sex reversal revealed 
that most aberrant mutations occur in the HMG domain, suggesting that DNA binding 
and bending properties are essential in sex determination (37, 97). It has been proposed 
that by affecting a dramatic conformational change in DNA, Sox factors are capable of 
bridging the gap between distal enhancers and proximal transcriptional elements, 
allowing for interaction between regulatory complexes separated by long distances in the 
genome (94). Furthermore, it has been demonstrated that the Sox HMG box has an 
adaptive tertiary structure, the formation of which is directed by DNA upon binding 
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consensus sequences (29, 142). The ability of the Sox HMG box to change tertiary 
structure depending on DNA-binding has led to the proposal that single Sox factors are 
capable of bending DNA to different degrees in a context-dependent manner, facilitating 
differential transcriptional control of genes (147).  
Functional roles of Sox factors are dependent on spatial, dose, and temporal context 
 Sox factors are expressed in nearly every tissue during embryogenesis and are 
emerging as a group of genes that are broadly expressed across a wide range of adult 
tissues as well. Individual Sox factors are expressed across many tissue and proliferating 
cell types, suggesting fundamental roles in cell maintenance. However, Sox factors 
exhibit some degree of cell- and tissue-specificity, in that they are expressed in multiple 
tissues but not in every cell found in those tissues. For example, Sox9 is expressed in the 
Sertoli cells of the testis, in chondrocytes during cartilage formation, and in a subset of 
epithelial cells of the small intestine and colon (39, 51, 143, 153). This characteristic of 
expression patterns that are not restricted to one organ systems or all cell types within 
tissues arising from the same germ layer suggests that Sox factors have a fundamental 
functional role in cell behavior across diverse tissue and cell types.  
The ability to bind the same DNA sequence is predictive of redundancy between 
different Sox factors and the potential to functionally compensate for one another (37, 
70). Compensatory mechanisms have been suggested by the observation that Sox5null and 
Sox6null mice each undergo chondrogenesis, but animals with deletions of both Sox5 and 
Sox6 fail to produce cartilage (120). These data imply that Sox5 and Sox6 are able to 
reciprocally compensate for one another and drive the development of cartilage.  
 Another important feature of Sox factors is that they can act in a dose-dependent 
manner. That is, varying levels of expression of a single Sox factor can elicit a variety of 
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responses in distinct cell and tissue types. It has been suggested that gradients of 
endogenous expression of Sox-factors across different cell types in a single tissue allow 
for different responses to the same exogenous signal (39, 40, 73, 132, 143). For example, 
data show that differing levels of Sox2 during development drive retinal tissue to adopt 
distinct phenotypes (132). Dose-dependent behavior of Sox factors was suggested for 
Sox9 in human patients suffering from campomelic dysplasia, a disorder defined by 
significant skeletal defects. It was observed that patients suffering from campomelic 
dysplasia in addition to sex reversal exhibited a varying range of phenotypic penetrance 
due to haploinsufficiency (40). Variable phenotypes as opposed to a true wild type vs. 
“knock-out” phenotypes in campomelic dysplasia suggest that Sox factors are able to 
exert functional effects on gene expression in a dose-dependent manner.  
In addition to behaving in a dose-dependent manner, Sox factors often exhibit 
temporal expression that may play an important role in the maintenance and 
differentiation of cellular lineages. The observed trend has been that the expression of 
Sox factors is maintained prior to cell fate decisions, then rapidly downregulated upon 
lineage commitment. This has been observed in the development of the testis, during 
which Sox9 and Sry undergo a change from upregulation to downregulation during 
precursor commitment to form Sertoli cells, as well as in dynamic expression patterns of 
Sox1-3 in neuroepithelial cell lineages (27, 44, 48, 70, 127, 137). Though still in the 
process of being thoroughly defined, the known transcriptional capabilities of Sox factors 
demonstrate that they are powerful regulators of cellular potency and developmental 
processes. 
 
  
8 
Sox17 is essential for gastrointestinal development 
The epithelial layers lining the esophagus, stomach, and intestine, as well as a 
majority of liver and pancreatic tissue, all arise from the definitive endoderm during 
embryonic development (reviewed by (148). Sox17, a member of the SoxF subgroup, was 
shown to be essential to the development of definitive endoderm in mammals, as had 
previously been demonstrated for Sox17 orthologues in Xenopus (55, 59). Mice deficient 
in Sox17 showed defects in the definitive endoderm beginning with endodermal 
induction. Specifically, there was an increase in apoptosis observed in the foregut along 
with defects in cellular expansion in the mid- and hindgut, resulting in embryonic 
lethality at 10.5 dpc (59). Recent studies have also demonstrated a role for SOX17 in the 
differentiation of human embryonic stem cells (HESCs). Overexpression of SOX17 in 
HESCs drove 78.51% of the cells to differentiate into definitive endoderm in the absence 
of cytokines, while treatment with Activin A, a cytokine known to promote formation of 
definitive endoderm, only drove one-third of HESCs to differentiate similarly (114). 
Additionally, further manipulation with growth factors associated with lineage-specific 
differentiation was successful in inducing the expression of early hepatic and pancreatic 
markers in SOX17-overexpressing HESCs (114). Taken together, these findings highlight 
a critical role for Sox17 in the development of the mammalian gastrointestinal tract. This 
established developmental role suggests that Sox factors are an important subject of study 
in the maintenance of stem cell populations in the organs of the adult gastrointestinal 
tract.  
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THE UPPER GI TRACT: ESOPHAGUS/STOMACH 
Maintenance and differentiation of cells in the upper gastrointestinal tract are 
important in facilitating the developmental formation and continued function of the 
normal esophagus and stomach. Due to common embryonic origin of the esophagus and 
trachea, any aberrant molecular signaling early in development can result in phenotypes 
that compromise not only the integrity of the digestive tract, but that of the airway and 
respiratory system as well. In the adult organism, esophageal and gastric epithelial 
homeostasis is governed by maintenance and differentiation of resident stem and 
progenitor cells (60). Aberrant proliferation or differentiation in these cell populations 
can lead to metaplastic pre-cancerous lesions that could ultimately result in functional 
deficits of the upper digestive tract. Therefore, an understanding of the regulatory factors 
governing development and maintenance of proper temporal and spatial cellular 
phenotypes within the upper gastrointestinal tract is essential for the characterization of a 
wide range of disorders affecting the esophagus and stomach.   
Stem cells in the esophagus  
The esophageal epithelium is arranged in two layers: the basal layer, consisting of 
cuboidal epithelial cells, and the suprabasal layer, comprised of polyhedral cells (74). 
Early research with radioactive thymidine-labeling studies demonstrated that cell division 
is restricted to the basal layer (74). These studies also demonstrated a relatively high rate 
of turnover in the esophageal epithelium, as nearly all of the basal epithelial cells were 
shown to divide in 3 to 5 days. More recent work has gone further to demonstrate that 
basal esophageal epithelial cells are arranged in clonal units (30, 134). Taken together, 
these data support the presence of an esophageal stem cell and stem cell niche in the basal 
layer of the esophageal epithelium. Furthermore, it has been shown that transit-
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amplifying progenitor cells generated by stem cells in the basal esophageal epithelium 
must enter the suprabasal layer before differentiating (30). This observation has led to the 
proposal that genetic changes must take place within progenitor cells prior to 
differentiation that allow them to generate appropriate cellular lineages once they enter 
the suprabasal layer (31). Significant genetic priming for differentiation suggests the 
involvement of potent transcriptional regulation, a functional requirement that makes Sox 
factors an attractive subject in esophageal stem cell biology.  
Stem cells in the stomach 
The human gastric epithelium consists of simple columnar epithelium and is 
divided into the cardia, fundus, and antrum (52). It is important to note that the murine 
stomach is divided differently, into forestomach lined with stratified squamous 
epithelium and hindstomach lined with simple columnar epithelium (61). Invaginations, 
called gastric pits, line the gastric epithelium, each containing 4 or 5 gastric glands, 
which house the gastric epithelial proliferative zone (61, 75). In both fundic and antral 
gastric pits, gastric epithelial stem cells reside at the neck of the glands and drive 
proliferation bi-directionally up and down the gland (60). However, fundic and antral pits 
differ in terms of cell types generated by their respective stem cells and also in terms of 
rates of regeneration, with the antral pits driving cellular turnover at a greater rate than 
the fundic pits (49, 60, 93). This difference in proliferation across separate zones of the 
same tissue suggests differential genetic regulation of stemness in gastric epithelial stem 
cell populations. The demonstrated ability of Sox factors to regulate proliferative 
potential and stemness makes them attractive candidates for regulation of proliferation 
across the gastric epithelium.  
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Evidence that Sox factors play a role in stem cell physiology of the upper GI tract 
 During development, Sox factors drive tissue specification processes along the 
axis of the forming upper gastrointestinal tract (102). The esophagus and stomach derive 
from the endodermal foregut and demonstrate similarities in terms of Sox expression. Of 
the Sox factors associated with the upper gastrointestinal tract (Table 1), Sox17 is 
expressed in the esophagus and stomach, while Sox18 expression is reported in the 
stomach alone (64, 106). Within the normal gastrointestinal tract, Sox2 shows expression 
in the esophagus and stomach, and its functional role in the upper gastrointestinal tract 
has been extensively characterized (77, 102). Interest in the role of Sox2 in the stomach 
was originally driven by the observation that Sox2 expression is markedly downregulated 
in gastric carcinomas, implicating aberrant expression of the gene with a loss of proper 
cellular homeostasis (see Table 2) (77). This early observation suggested that Sox2 might 
also play a role in maintenance and differentiation processes of gastric stem cell 
populations.   
Sox2 in the development and normal biology of the esophagus and stomach 
During early development of the esophagus, Sox2 is expressed in all cells of the 
endodermal foregut, but at E9.5 expression levels segregate in a dorsal-ventral manner 
that results in relatively high expression in the developing esophagus and relatively low 
expression in the developing trachea (102). Abnormal down-regulation of Sox2 
expression during embryogenesis was observed to result in esophageal atresia (EA) and 
tracheoesophageal fistula (TEF), with Sox2 protein undetectable at the site of TEF (92, 
102). These data demonstrate that normal expression of Sox2 is required for appropriate 
tracheoesophageal morphogenesis.  
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In the case of murine gastric development, Sox2 levels are first expressed across 
the entire embryonic stomach to the duodenum, but decrease in the hindstomach while 
remaining relatively high in the forestomach later in gestation (102). This gradient in 
expression levels is mirrored in adult human stomach, with Sox2 expression decreasing 
from fundus to antrum and becoming very low at the pyloric sphincter (135). The change 
in expression of Sox2 along the developing esophagus and stomach implies a dose-
dependent role in the establishment of cellular fate, as high levels of Sox2 appear to 
specify an esophageal or gastric fate, while low levels of Sox2 appear to drive adaptation 
of tracheal or intestinal fates.  
Sox2 plays an important role in cellular differentiation processes that establish the 
structure of epithelia formed along the length of the upper gastrointestinal tract (102). It 
has been proposed that high levels of Sox2 during murine development drive the 
formation of stratified, squamous epithelium while low levels direct cell fate toward 
columnar epithelium (92). The change in mucosal structure from stratified squamous 
epithelium in the murine forestomach to columnar epithelium in the hindstomach 
supports this concept. Furthermore, mice exhibiting TEF concurrent with decreased 
levels of Sox2 expression exhibit ectopic columnar epithelium at the site of TEF, in 
contrast to wild-type littermates, which have physiologically normal squamous 
epithelium throughout the esophagus (92). In addition to playing a role in the 
development of the structural anatomy of the upper gastrointestinal tract, Sox2 appears to 
be important in the establishment of proper epithelial subtypes along the esophageal-
gastric axis.  
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Roles for Sox2 in precancerous and cancerous lesions of the esophagus and stomach 
Cellular changes in precancerous and cancerous lesions of the esophagus and 
stomach suggest that Sox2 may also play an active role in the maintenance and 
differentiation of cells in adult tissues of the upper GI tract. Sox2 appears to be important 
for maintaining a gastric phenotype in epithelial cells in the stomach (102, 131, 135). 
Failure to maintain gastric phenotype in gastric epithelial cell populations can lead to 
intestinal metaplasia (IM), or the precancerous conversion of gastric epithelial cells to 
intestinal epithelial cells (135).  Studies of human tissue from patients suffering from IM 
showed that Sox2 is progressively down-regulated throughout progression from normal 
gastric epithelium to widespread intestinal metaplasia (135). A loss of Sox2 was also 
observed in both a rat model of intestinal metaplasia and samples from human cases of 
Barrett’s esophagus (9). These observations are strikingly similar to the finding that 
segregation of tissue expressing Sox2 from tissue not expressing Sox2 early in 
development coincides with the formation of a gastric-duodenal junction (92). Taken 
together, these studies suggest that Sox2 is critical in maintaining a distinct boundary 
between the epithelia of the esophagus and stomach and intestinal epithelia.  
Sox2 expression levels have also been shown to associate with other distinct 
markers of a gastric phenotype. For example, Sox2 upregulates the expression of the 
stomach-specific pepsin precursor pepsinogen A in gastric cell lines as well as ectopically 
in colon cancer cell lines (131). Conversely, interference with Sox2 expression causes a 
significant decrease in pepsinogen A, suggesting a pivotal role for Sox2 in pepsinogen A 
expression (131). Further evidence for Sox2 maintenance of a gastric phenotype is found 
by comparing expression of gastric-specific mucins versus that of the intestinal-specific 
mucin. When Sox2 levels decrease, there is a progression from normal gastric phenotype 
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to intestinal metaplasia, and expression of gastric-specific mucin decreases, while levels 
of intestinal-specific mucin increase (135). To summarize these studies, high levels of 
Sox2 are associated with the upregulation of markers for differentiation specific to the 
gastric epithelium, while decreasing levels of Sox2 correlate with the upregulation of a 
lineage-specific marker normally restricted to the intestinal epithelium.  
Gastric cancer is commonly associated with a down-regulation of Sox2 (77). It 
has been proposed that methylation and epigenetic silencing of Sox2 in gastric cancer 
leads to progressively aberrant proliferation of the gastric epithelium, an idea supported 
by the clinical observation that patients presenting with gastric carcinomas which exhibit 
methylation of the Sox2 gene face poorer prognoses than those without Sox2 methylation 
(92). Reinforcing the idea that Sox2 might play a tumor-suppressive role in the gastric 
epithelium is the observation that exogenous overexpression of Sox2 has an inhibitory 
effect on proliferation of gastric carcinoma cells in vitro, an effect that progresses to 
morphological change and apoptosis with persistent overexpression of Sox2 (92). 
Interestingly, a recent study on human esophageal squamous cell carcinoma reported that 
15% of patients had amplification of Sox2 in tissue samples from this tumor type (19). 
This study raises the possibility that Sox2 may play a different regulatory role in the 
esophagus than it does in the stomach. Taken as a whole, the above data suggests that 
Sox2 is a critical player in the maintenance of a gastric epithelial cellular phenotype, as 
well as a regulator of normal proliferation of the esophageal and gastric epithelia. 
 
LOWER GI TRACT 
The lower gastrointestinal tract, which includes the small intestine and colon, 
functions to absorb nutrients in the digestive tract through a complex interaction between 
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epithelial, vascular, nervous, and lymphatic tissues. In addition, epithelial tissue lining the 
luminal surfaces of the lower gastrointestinal tract must be specialized for absorptive 
function while simultaneously maintaining a barrier against the bacteria-rich digestive 
lumen in order to preserve the sterility of the rest of the body. A majority of epithelial 
cells carry out highly specialized functions in the intestinal and colonic epithelia and 
undergo rapid turnover rates that result in replacement of nearly the entire epithelium 
every 7 days (154). This rate of rapid renewal combined with the need to sustain 
physiological and cellular homeostasis emphasizes the importance of regulation of 
cellular maintenance and differentiation in the small intestine and colon. The intestinal 
epithelium has been an attractive target for the study of cellular maintenance and 
differentiation, especially in terms of potent mitogenic signaling via the Wnt pathway. 
The role of the intestinal and colonic epithelia in inflammatory bowel disease (IBD) as 
well as high rates of colon cancer has fueled a long-standing interest in maintenance and 
differentiation of this tissue type.  
Stem cells of the small intestine and colon 
 The proliferative region of the intestinal and colonic epithelia has long been 
known to reside in the crypts of Lieberkuhn (22-24). Division of multipotent stem cells 
and differentiation of progenitor cell populations in the crypts drives the replacement of 
terminally differentiated cells on the villi. These cells are then sloughed into the lumen 
facilitating epithelial renewal. In addition to generating absorptive enterocytes that 
comprise a majority of the terminally differentiated epithelium, the intestinal epithelial 
stem cells also give rise to secretory lineages that include goblet and enteroendocrine 
cells in the small intestine and colon, as well as Paneth cells, which are restricted to the 
small intestine (22-25). Strong evidence points to the Wnt/β-catenin pathway as a key 
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mitogenic signaling cascade driving crypt proliferation (26). Significantly less is 
understood in terms of how Wnt/β-catenin signaling is regulated in order to elicit 
appropriate and distinct responses from cells responsible for controlling stem cell 
maintenance versus differentiation in the small intestine and colonic epithelia. Recent 
advances in the understanding of Sox function in the intestinal epithelium has revealed 
that this family of transcription factors plays an important role in the downstream 
regulation of Wnt activity (72).  
High rates of proliferation, differentiation, and cell turnover make the intestinal 
epithelium a useful model system to study the role of Sox factors in regulating cellular 
homeostasis in the gastrointestinal tract. Screening for mRNA has revealed expression of 
Sox2, Sox3, Sox4, Sox5, Sox6, Sox7, Sox9, Sox10, Sox11, Sox17 and Sox18 in whole small 
intestine and colon (see Table 1). A caveat concerning mRNA expression is that some 
data is reported from whole-tissue analysis. Therefore, some Sox factors reported to be 
expressed in the intestine might be specific to non-epithelial cell types, such as smooth 
muscle and enteric nerve cells, which will not be addressed in this review. However, the 
role of Sox9 in the epithelium of the lower gastrointestinal tract has been extensively 
characterized (10, 13, 119). Studies utilizing the intestine as a model system have been 
instrumental in revealing important epithelial roles for Sox4 and Sox17 as well (119). 
Data suggests that Sox factors contribute to the proper regulation of the proliferative cell 
populations in the intestinal and colonic epithelium. 
Sox9 regulates proliferation in the small intestine and colon  
The most extensively studied Sox factor in the intestinal epithelium is Sox9, which 
has been shown to be primarily expressed in the stem/progenitor region of the crypts in 
the small intestine and colon, with some limited expression observed in cells throughout 
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the villi of the small intestine (13, 39, 58). The localization of Sox9 to the proliferative 
compartment of the intestinal epithelium supported a possible involvement in the Wnt/β-
catenin pathway, as Wnt is known to drive proliferation in the crypts. Disruption of Wnt 
signaling in early post-natal stages was shown to completely ablate Sox9 expression in 
the intestinal and colonic epithelia, identifying Sox9 as a downstream target of Wnt (13).  
 Other studies demonstrate that Sox9 plays an important role in the regulation of 
cell fate and differentiation. Sox9 expression has been shown to prevent cellular 
differentiation into Muc2-expressing goblet cells in vitro, implicating Sox9 in the 
maintenance of a non-differentiated population of putative stem/progenitor cells (13). 
Furthermore, Sox9 was shown to repress genes associated with terminally differentiated 
cell types, including CDX2 in intestinal epithelium and carcinoembryonic antigen (CEA) 
in colonic epithelium, in vitro (13, 58). More recently, conditional embryonic Sox9 
knockout mice were shown to lack Paneth cells in the intestinal epithelium following 
birth (10, 89). Taken together, these data suggest that Sox9 plays a complex regulatory 
role in cell fate decisions and differentiation downstream of Wnt.   
Findings suggestive of Sox9 association with a non-differentiated pool of cells 
located in the classical “stem cell niche” of the intestinal and colonic epithelia provide 
evidence that Sox9 might also play a role in the maintenance of a stem/progenitor 
phenotype. However, given the multitude of proposed functional roles for Sox9, it can 
become conceptually difficult to grasp how a single gene appropriately regulates different 
cellular responses across the epithelium. Sox9 is expressed at variable levels in the 
intestinal epithelium and these levels have been shown to correlate with different cellular 
phenotypes, reinforcing earlier observations that Sox factors function in dose-dependent 
manners (39). Specifically, recent studies utilizing a BAC transgenic mouse model, in 
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which regulatory elements of Sox9 drive the expression of EGFP, classified Sox9 
expression as “sublow”, “low”, and “high” (39, 45). Sox9 high-expressing cells were 
demonstrated to be fully differentiated enteroendocrine cells, as well as the only Sox9-
positive cell type observed in villi, while Sox9 low-expressing cells were shown to 
correlate with increased expression of established functional markers of intestinal 
epithelial stem cells (39). Recently, it was shown that Sox9 low-expressing cells are 
multipotent and self-renewing in vitro and that Sox9 “sublow”-expressing cells are 
enriched for markers of proliferation as well as early markers of differentiation, 
suggesting that Sox9 “sublow” expression corresponds to the transit-amplifying cells of 
the intestinal epithelium (45). In vitro studies have shown that Sox9 inhibits the 
transcription of cMyc and cyclinD1 by β-catenin/TCF, suggesting that Sox9 might 
regulate Wnt signaling via a dose-dependent negative feedback loop (10, 13, 39). One 
model proposes that Sox9 has a dose-dependent, inverse relationship with proliferative 
potential in response to Wnt signaling in the intestinal crypts (39). This proposal is 
strongly reinforced by the identification of the Sox9 “sublow”-expressing putative transit 
amplifying population, wherein very low levels of Sox9 would be expected to result in an 
upregulation of cMyc and cyclinD1 in response to Wnt signals, potentiating the rapid 
proliferation needed to constantly renew the terminally differentiated cells of the 
intestinal epithelium (45). Interestingly, very high levels of Sox9 are expressed in the 
enteroendocrine populations, which develop in the absence of Wnt-signalling (39, 146).  
This observation implicates a Wnt-independent regulatory role for Sox9 in post-mitotic 
cell populations.  
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Sox9 and colon cancer 
In addition to apparent regulatory roles in the normal biology of the small 
intestine and colon, increased expression of Sox9 has been noted in colon cancer (see 
Table 2). Screening of several human colon cancer cell lines revealed that Sox9 mRNA 
and protein were upregulated over controls (see Table 3) (13). Immunohistochemistry of 
serial sections of human adenocarcinomatous colon also demonstrated upregulated 
expression of Sox9 protein in an ectopic pattern that co-localized with increased nuclear 
localization of β-catenin (13). Upon first inspection, these data appear to be in direct 
conflict with the observation that low levels of Sox9 might maintain a non-differentiated 
cellular phenotype, as overexpression of Sox9 in non-transformed small intestine cell 
lines or colon cancer cell lines decrease proliferation and prevent differentiation into both 
secretory and absorptive lineages (39, 58). However, mRNA analysis of whole tissues 
and cell lines does not account for the level of Sox9 expression in individual cells, which 
is of critical importance due to the dose-dependent behavior of Sox factors. A tumor 
expressing higher levels of Sox9 mRNA might do so because there is an increase in the 
number of Sox9 “low” stem cells and Sox9 “sublow” progenitor cells over negative 
controls. In this case, there would be an increase in absolute mRNA levels of Sox9 due to 
ectopic cellular expression that does not necessarily indicate an increase in Sox9 
expression in cells that express the gene under normal conditions.  
 In addition, downregulation of Sox9 was shown to be sufficient to allow 
increased expression of CEA in colonic adenocarcinomas in vitro, while overexpression 
of Sox9 was sufficient to prevent expression of CEA in the same cell lines (58). The 
observation that Sox9 regulates CEA expression by colonic adenocarcinomas in vitro is 
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clinically relevant, as CEA is associated with anti-apoptotic effects in colon cancer that 
can lead to metastasis (91, 151).  
Jay, et al. hypothesized that Sox9 might have pro-apoptotic effects in colonic 
adenocarcinoma and demonstrated that induced expression of Sox9 leads to an increase in 
apoptosis in colon cancer cell lines in vitro (58). These data supported the prior 
association of CEA with decreased apoptosis and the authors’ demonstration of the ability 
of Sox9 to indirectly inhibit the CEA promoter, leading to the conclusion that regulation 
of Sox9 might be an attractive approach to mediating anti-apoptotic effects of CEA in 
aggressive colon cancers (58, 151). A mouse model exhibiting Sox9-knockout specific to 
the intestinal epithelium revealed a significant change in colonic epithelial morphology, 
with pronounced crypt hyperplasia and the formation of atypical, “villus-like” structures 
protruding into the lumen (10). Supporting previous observations that Sox9 might play a 
pro-apoptotic role in colon cancer, Sox9 knockout mice exhibited a high rate of 
spontaneous microadenoma formation (10). These emerging data regarding roles of Sox9 
in colon cancer suggest that the gene is not only important in the development and 
progression of tumors, but might also be exploited toward diagnostic and therapeutic 
ends.  
Preliminary evidence suggests roles for Sox4 and Sox17 in the small intestine and 
colon 
 In addition to Sox9, limited yet intriguing evidence has emerged that suggests 
other Sox factors also have important regulatory roles in maintenance and differentiation 
in the intestinal epithelium. Interestingly, like Sox9, Sox4 and Sox17 have both been 
shown to differentially regulate β-catenin activity in colon cancer in vitro, leading to 
changes in cellular proliferation (64, 119). It was found that Sox17 is downregulated in 
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spontaneous adenomas of APC-min mice, while Sox4 is upregulated (119). Expression 
analysis was supported by data revealing that forced expression of Sox17 in colon 
carcinoma cells resulted in a downregulation of β-catenin/TCF activity and a decrease in 
proliferation, while Sox4 overexpression had the opposite effect (64, 119). These data 
show that individual Sox factors differentially regulate intestinal epithelial proliferation 
and suggest different ratios of Sox factors in the same cell may work in concert to control 
proliferation. Furthermore, the observation that both Sox9 and Sox17 negatively regulate 
Wnt activity is suggestive of overlapping roles for Sox factors in the intestinal epithelium.  
 
PANCREAS  
The study of pancreatic development and cellular homeostasis is arguably one of 
the most dedicated efforts to translate basic cell biology to clinically applicable therapies. 
The pancreas resides at an epicenter of questions concerning both individual quality of 
life and public health issues, as both type I and type II diabetes present with significant co 
morbidity at increasingly high rates in the general population, and are projected to affect 
366 million individuals globally by 2030 (149).  Of special interest is the idea that 
clinical replacement of absent or dysfunctional β-islet cells could greatly reduce the 
wide-sweeping impact of diabetes on the healthcare system as a whole.  
Stem cells in the pancreas 
The pancreas is a complex organ that fulfills both exocrine and endocrine 
functions. A majority of the pancreas is dedicated to exocrine function, producing 
enzymes essential for the digestion of macronutrients. The functional unit of the 
endocrine pancreas comprises specialized endocrine cells in the islets of Langerhans, 
which are interspersed throughout the exocrine pancreas. The islets consist of α-cells 
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(glucagon-secreting), β-cells (insulin-secreting), δ-cells (somatostatin-secreting), ε-cells 
(ghrelin-secreting), and PP-cells (pancreatic polypeptide-secreting). The regulation of 
pancreatic endocrine cell behavior is vital for homeostasis of the organism and an integral 
component in the pathogenesis of diabetes. As such, a great deal of attention has been 
devoted to understanding putative stem cell populations within the adult pancreas. To 
date, the precise location of pancreatic stem cells remains debated, but evidence suggests 
that ductal, acinar, and islet cells are capable of contributing to pancreatic regeneration 
(reviewed by (15). Strikingly, recent evidence has also shown that mature β-cells are 
capable of driving β-cell regeneration under both normal conditions and following injury 
(35, 90). The ability to modify proliferation strategies either intrinsically or in response to 
extrinsic signaling is suggestive of complex and context-specific transcriptional 
regulation of putative stem cell populations in the pancreas.  
 Sox factors have been an attractive target of research in pancreatic physiology and 
disease due to their ability to modulate the proliferative capacity of stem and progenitor 
cells. In terms of organs of the gastrointestinal tract, the breadth of Sox factors known to 
be expressed in the pancreas is rivaled only by that expressed in the intestine. Many Sox 
genes have been localized to the pancreas, including Sox4, Sox6, Sox9, and Sox13 (see 
Table 1). (57, 62, 116, 150). Sox4, Sox6, Sox9, and Sox13 are especially noteworthy in 
that they have been shown to have functional roles in pancreatic physiology. By contrast, 
the current knowledge of other Sox factors in the pancreas is restricted to expression 
analysis data, with no clear functional roles yet determined. This discussion of Sox 
factors in the pancreas will therefore focus on evidence for functional roles of Sox 
expression in the maintenance and differentiation of pancreatic cell populations.   
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Sox9 in pancreatic development 
 Sox expression in the developing pancreas is dynamic, with gene expression 
patterns and levels changing over the course of development. Sox9, the most studied Sox-
factor in the pancreas, has been shown to exhibit dynamic expression throughout 
ontogeny. During murine development, Sox9 undergoes changes in expression level that 
span broad expression at E9.5 to restricted, downregulated expression by late gestation 
(80). Spatial expression of Sox9 has been shown to associate with the entire pancreatic 
epithelium at E10.5-E12.5, but at late gestation is restricted mostly to the islets of 
Langerhans (80, 116). Lineage-tracing studies have shown that cells expressing Sox9 in 
the embryonic pancreas co-localize with multipotent progenitor cells that give rise to the 
pancreatic endocrine lineages, as well as to early pancreatic exocrine progenitors (115). 
These data show that Sox9 marks a population of cells that give rise to all pancreatic cell 
types.  
Sox4 shows similar changes in expression across pancreatic development as it is 
expressed at high levels early in development and undergoes downregulation between 
E12.5 and E15.5, but exhibits subsequent, slight upregulation in adult islets (80, 116). 
These studies support the notion that dynamic changes in Sox factor expression are a 
common theme in normal pancreatic development and suggest that Sox factors may 
regulate the timing of specific processes within the developmental timeframe.  
 Gene knockout experiments resulting in pancreas-specific ablation of Sox9 in 
mice have demonstrated that Sox9 is essential to pancreatic development, as knockout 
mutants died shortly after birth due to dehydration and elevated blood glucose levels, and 
displayed severely abnormal gross pancreatic morphology (116). In addition, pancreas-
specific Sox9 knockout mice exhibited heterogeneous phenotypes, with either a complete 
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absence of pancreatic endocrine cells or only sporadic representations of these cell types, 
suggesting that Sox9 plays a critical role in the cellular development of the endocrine 
pancreas (116). Heterozygous mutants for pancreas-specific Sox9 deficiency are viable 
and fertile and exhibit normal gross pancreatic morphology. Interestingly, upon 
histological examination, heterozygous mutants are shown to have significantly reduced 
numbers of pancreatic endocrine cells that are functionally normal in terms of mRNA 
expression of insulin processing enzymes and insulin secretion (115). These data suggest 
that while Sox9 is important in terms of gross pancreatic development and early 
differentiation of pancreatic endocrine lineages, it is not essential for normal function of 
endocrine cells once they have undergone cell fate decisions. Furthermore, the authors 
note that varying degrees of deficit observed between haploinsufficiency and complete 
knockout are indicative of a dose-dependent role of Sox9 in the endocrine pancreas (115). 
This notion is further supported by the observation that haploinsufficiency of Sox9 in 
human patients suffering from campomelic dysplasia results in abnormal islet cell 
morphology (96). 
Sox4 in pancreatic development 
 Similar to Sox9, expression patterns of Sox4 are broad across pancreatic buds in 
early pancreatic development and restricted to the endocrine cells of the islets by 
adulthood (80, 150).  Interestingly, observations regarding functional effects of Sox4 have 
been very similar to those made for Sox9. Due to embryonic lethal cardiac defects in 
homozygous Sox4null mutants, all experiments examining pancreatic roles of Sox4 past 
E11.5 were conducted ex vivo on explant cultures from mutant embryos (113, 150). There 
was no observed difference in growth rate between wild type, heterozygous, and 
homozygous, Sox4 deficient explant cultures. Further examination revealed that 
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heterozygous mutant and wild-type cultures were able to generate islet cells in vitro that 
expressed insulin and glucagon, where homozygous mutants were not (113, 150). 
However, islet cells from Sox4 homozygous knockout mice continued to exhibit normal 
markers of endocrine cell lineages, albeit at lower expression levels relative to 
heterozygous mutant and wild type explant cultures (113, 150). Decreased endocrine cell 
differentiation in Sox4null explant cultures suggests that Sox4 plays a regulatory role in the 
expansion of the pancreatic endocrine compartment.  
 Possible functional roles of Sox4 and Sox9 in terms of regulating the cellular 
population of the endocrine pancreas are similar in that both seem to contribute to 
pancreatic cell number during development without affecting normal endocrine functions 
in cells that are able to properly differentiate. Wilson, et al conclude that Sox4, like Sox9,  
is a requisite component of normal endocrine expansion in the developing pancreas (113, 
150). The similarities between observed functional roles of pancreatic Sox4 and Sox9 
suggest that the two might play similar roles in the genesis of pancreatic endocrine cells. 
The regulation of pancreatic endocrine differentiation by Sox4 and Sox9 represents an 
area of research that warrants further investigation.  
Sox6 is associated with hyperinsulinemia  
 In terms of functional maintenance of the adult pancreatic phenotype, Sox6 is 
emerging as a potentially powerful mediator of gene regulation and cellular maintenance 
in pancreatic β-cells. Interest in pancreatic Sox6 is supported by observations that 
persistent downregulation of Sox6 is strongly associated with hyperinsulinemia in obese 
mice (56). Furthermore, downregulation of Sox6 coincident with hyperinsulinemia was 
correlated with high-fat diet treatments in normal mice, as well as genetic defects leading 
to obesity (56). These data implicate Sox6 in the dysregulation of insulin signaling 
26 
associated with type II diabetes mellitus. Whereas Sox6 is shown to localize to normal 
adult β-cells and suppress genes implicated in β-cell proliferation, downregulation of 
Sox6 has been shown to reduce this suppression and lead to an increase in glucose-
stimulated insulin secretion (56). Furthermore, a reduction in levels of Sox6 leads to 
proliferation and expansion of β-cell populations. Immunoprecipitation assays suggest 
that Sox6 inhibits proliferation by forming complexes with β-catenin and serves as a 
cofactor for histone modifications that suppress downstream activities of β-catenin (57). 
Interestingly, a recent study utilizing bivariate genome-wide association study (GWAS) 
examination of polymorphisms present in obesity and osteoporosis in human males 
indicated that SOX6 is strongly associated with both increased body mass index and 
decreased bone mineral density (81). These data would suggest that Sox6 plays roles both 
in obesity-associated insulin regulation as well as regulation of β-cell proliferation in the 
adult pancreas.   
Sox13 is a diabetes-associated autoantigen 
Sox13 is expressed throughout pancreatic development and in adult islet cells, has 
been implicated in functional deficiencies in β-islet cells in type I diabetes mellitus (62, 
80, 150). Surveys of type I and type II diabetes patients, as well as control subjects, 
demonstrated a higher occurrence of Sox13 autoantigens in the diabetic population (62). 
Furthermore, Sox13 autoantigens were significantly upregulated in type I patients 
compared to patients with type II diabetes (62). While these data demonstrate a strong 
correlation to autoimmune-associated type I diabetes, the authors are careful to point out 
that no definitive conclusions can be reached as to whether or not Sox13 autoantigens are 
causative of, or consequential to type I diabetes.  
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Sox2 plays a role in the development of pancreatic cancer 
In addition to roles in development and maintenance of pancreatic cellular 
phenotypes, Sox factors have been implicated in aberrant signaling processes leading to 
pancreatic cancer. As previously described in regards to gastric cancer, Sox2 is also 
associated with abnormal cell types observed in pancreatic intraepithelial neoplasia 
(PanIN).  Observations that Sox2 is upregulated in PanIN correlate with the observed 
upregulation of extrapancreatic epithelial markers (100).  Sox2 has been shown to be 
essential for the maintenance of gastric epithelial phenotypes and abnormal expression of 
Sox2 is associated with the development of gastric cancers through the failure to maintain 
this phenotype (92). Interestingly, levels of Sox2 in PanIN are upregulated over normal 
pancreatic expression levels to levels normally seen in the gastric fundus and antrum 
(100).  This, along with the identification of pepsinogen C and the gastric-specific mucin 
Muc6 in PanIN, suggests that upregulation of Sox2 in PanIN drives pancreatic cells to 
adopt an abnormal gastric epithelial phenotype (100). These studies continue to 
underscore the spatio-temporal and dose-dependent roles of Sox family transcription 
factors in maintenance and differentiation processes in the gastrointestinal tract.  
 
HEPATOBILIARY SYSTEM 
 The hepatobiliary system, which consists of the liver, gallbladder, and bile ducts, 
plays a central role in proper function of the gastrointestinal tract. The liver serves a wide 
range of functions essential for both digestion and overall metabolism, acting as an 
exocrine organ as well as a filter for the systemic circulation. Homeostasis within 
hepatocyte populations, the functional parenchymal cells of the liver, is essential for 
proper hepatobiliary function and homeostasis of the entire organism. Pathologies 
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resulting in insufficient or aberrantly upregulated expansion of hepatocytes, such as 
cirrhosis or hepatocellular carcinoma, respectively, present clinical problems as well as 
significant losses in quality of life for patients.   
Stem cells of the hepatobiliary system 
 The liver is compromised of individual functional units called hepatic lobules. 
Each lobule contains a portal triad consisting of a portal vein, hepatic artery, and bile 
duct, as well as hepatocytes, which are organized into rows called hepatic plates. Blood 
flows from the portal vein past the hepatocytes, which interact with the venous blood via 
a special fenestrated endothelium. After flowing past the hepatic plates, blood drains into 
the central vein, located opposite of the portal triad in the hepatic lobule (83). Normal 
hepatocyte turnover is slow, with hepatocyte lifespan having been calculated at 
approximately 200-300 days (18). Despite this low basal rate of turnover, the liver 
demonstrates remarkable regenerative characteristics following substantial loss of cells, 
as in the case of partial hepatectomy. In rats, the liver has been observed to regenerate 
and regain its original cell number in just 3-4 days following partial hepatectomy (17, 
126). The rapid rate of regeneration lends itself to clinical benefit in liver transplantation, 
as it facilitates the use of living donors. Interestingly, radioactive thymidine-labeling 
studies have demonstrated that this tissue-regenerative process is driven by mature 
hepatocytes (17, 126). Stem cell populations in the liver do not appear to make significant 
contributions to regeneration, except in cases where hepatocytes are damaged, such as 
following the administration of toxic pharmacologic agents in animal models (36). When 
hepatocytes are significantly damaged, their regeneration appears to be dependent on a 
hepatic stem cell population. Progenitor cells of the liver, termed “oval cells”, are derived 
from a non-hepatocyte precursor and are classically viewed as bi-potential progenitors, 
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capable of giving rise to both hepatic and biliary epithelial cells (4, 144). The ability to 
undergo fate decisions between hepatic and biliary lineages is indicative of precise 
transcriptional regulation of genes controlling differentiation processes in hepatobiliary 
progenitor populations.   
 In addition, complex regenerative strategies of the liver suggest powerful 
molecular regulatory mechanisms that are capable of controlling regeneration 
differentially in homeostatic and pathologic states. Hepatocyte contribution to cellular 
regeneration following partial hepatectomy represents a scenario in which tight control of 
proliferative capacity would be essential in order to trigger mature cells to divide but also 
prevent aberrant growth once proper cell number was restored. The proven ability of Sox 
factors to regulate “stemness” in other tissues makes their potential roles in hepatobiliary 
stem and progenitor cell populations especially interesting. However, despite an 
increasingly detailed understanding of hepatic regeneration, the role of Sox factors in the 
hepatobiliary system remains poorly understood. Early research has revealed basic roles 
and produced expression data for a handful of Sox factors in the hepatobiliary system, 
including Sox9 and Sox17 (see Table 1). However, no single Sox factor has emerged as 
being central to hepatobiliary stem cell populations.   
Sox9 and Sox17 contribute to biliary development 
 Recent research has begun to define emerging roles for Sox9 and Sox17 in the 
development of biliary ducts (7, 136). Biliary tubulogenesis proceeds via a two-step 
process, starting first with the differentiation of hepatoblasts into cholangiocytes followed 
by ductal morphogenesis, with cellular asymmetry (hepatoblasts v. cholangiocytes) 
between the parenchymal and portal regions of the developing duct maintained 
throughout tubulogenesis (7). Throughout the process of tubulogenesis, Sox9 is 
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preferentially expressed on the portal/biliary side of the developing duct, with no 
apparent expression in the parenchymal/liver region from E10.5 onward. Postnatal 
expression of Sox9 was found to be restricted to small ducts of the biliary system (7). 
Interestingly, liver-specific knockout of Sox9 driven by Alfp-Cre did not result in aberrant 
biliary duct formation. Rather, Sox9 knockout animals developed normal biliary ducts, 
but at a significantly slower rate than wild-type animals. Furthermore, Sox9 was found to 
regulate the expression of other genes implicated in development, including genes in the 
Notch and TGFβ pathways (7). These data demonstrate that Sox9 plays a critical role in 
the timing of biliary tubulogenesis, but also suggest that other compensatory mechanisms 
or signaling pathways exist that ultimately make Sox9 non-essential for biliary duct 
development.  
 In contrast to Sox9, recent data suggests that Sox17 is required for biliary 
development, specifically for the development of the gallbladder. Expressed throughout 
the foregut endoderm early in development, Sox17 later becomes restricted to the 
gallbladder region of the foregut, between the hepatic and pancreatic buds (136). 
Interestingly, early expression of Sox17 overlaps with markers for pancreatic fate, but 
with biliary induction later in development, Sox17 is preferentially expressed in biliary 
primordium only (123). Tissue-specific knockout of Sox17 results in improper 
positioning of the endoderm, consequently causing not only a lack of gallbladder 
development, but also resulting in ectopic development of pancreatic cells in the 
anatomical location of the gallbladder (123, 136). Conversely, continued expression of 
Sox17 throughout development in cells also expressing early pancreatic markers resulted 
in the suppression of pancreatic development (123). These data demonstrate that Sox17 is 
essential for the segregation and development of biliary primordium from early foregut 
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cells that give rise to both pancreatic and biliary cells. Sox17 therefore appears to play an 
important role in fate specification during gallbladder and pancreatic development in the 
hepatobiliary system.  
Preliminary findings point to wider roles for Sox factors in the hepatobiliary system 
 Aside from data generated by emerging biliary developmental research, Sox 
factors remain mostly uncharacterized in the hepatobiliary system, especially in terms of 
possible roles in hepatoblast maintenance and differentiation in the liver. Sox2 has been 
shown to be upregulated in Hep-12 cells while Sox7 and Sox17 have been overexpressed 
in human embryonic stem cells to drive differentiation toward hepatic-like phenotypes in 
vitro, but functional roles of these Sox factors in normal hepatic development and 
hepatoblast maintenance remain undefined (114, 155). Additionally, Sox13 has been 
identified as an autoantigen in primary biliary cirrhosis while Sox2 is upregulated in 
tumors of the ampulla of vater (38, 108). Despite these findings, Sox factors in general 
are poorly described in pathogenesis in the hepatobiliary system. Data supporting 
powerful regulatory roles of Sox factors in stem cell populations of other gastrointestinal 
tissues suggests that the role of Sox factors in the liver is an area deserving of further 
investigation. 
 
CONCLUSION 
 Diseases related to maintenance and differentiation of cells within the 
gastrointestinal tract, such as diabetes, colon cancer, and cirrhosis, affect a significant 
portion of the general population and often cause physiological consequences that 
negatively impact quality of life for affected individuals. An emerging understanding of 
tissue-specific stem cells holds significant promise toward the development of the next 
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generation of advanced clinical therapies, but the understanding of molecular regulation 
of these stem cells remains rudimentary. Initial studies have identified Sox factors as key 
players in the processes of stem cell maintenance and differentiation across nearly all 
organ systems in the gastrointestinal tract.  
Sox factors possess attractive functional capabilities that allow them to serve as 
versatile and powerful regulators of transcriptional activity. To date, multidisciplinary 
research has yielded sufficient data to reach general conclusions concerning members of 
the Sox family of genes. In simplest terms, the Sox family is made up of genes that 
behave as classical transcription factors, but also have the ability to affect dramatic 
conformational changes through DNA bending. The ability to physically alter the shape 
of DNA has the potential to allow for the joining of distal enhancing elements with 
proximal transcriptional machinery, as well as allow for inhibitory effects.  
Sox factors are attractive from a research standpoint in adult tissue due to their 
broad expression patterns, implication in maintenance of stem cell populations, and 
context-dependent functional roles. In large organ systems, such as the gastrointestinal 
tract, Sox factors have the potential to reveal unifying themes across organs that are 
functionally dissimilar, but derived from the same germ layer. Additionally, the feature of 
dose-dependent behavior might allow Sox factors to differentially modulate 
transcriptional responses to mitogenic signals, regulating proliferative potential in stem 
and progenitor cell populations.  
 From a translational standpoint, the ability to identify and manipulate cell 
populations via Sox function could lead to the directed control of stem cell populations in 
vivo. Additionally, understanding Sox function could allow for the in vitro expansion and 
autologous transplantation of gastrointestinal cells and tissues, a long-standing 
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therapeutic ideal of stem cell research. Dose-dependency and redundancy might allow 
Sox factors to be exploited in a manner that allows for the “fine-tuning” of healthy and 
diseased cells at the genetic level.  
Despite recent advances in functional characterization of Sox factors, many 
important questions regarding the roles of specific SOX genes in the gastrointestinal tract 
remain. One significant area that merits increased investigation is the expression and role 
of Sox factors in hepatobiliary physiology. While members of the Sox family have been 
used to mark a hepatic lineage in embryonic stem cell differentiation studies and 
described in terms of hepatic angiogenesis, no data exists describing possible roles for 
Sox in terms of hepatocyte function and proliferation (85, 123). Additionally, the ability 
of Sox factors to dramatically bend DNA warrants further investigation toward the 
functional role of Sox-mediated structural and higher-order genomic changes in stem cell 
populations. The elucidation of transcriptional roles for Sox factors might be limited by 
conventional genetic assays. Standard techniques employed to detect direct downstream 
targets of transcription factors in proximal promoter regions could theoretically prove 
inefficient in detecting distal Sox target genes that are activated through DNA bending 
and therefore not amenable to this form of detection. The development of novel technical 
approaches to overcome this obstacle is vital to the further study of Sox factors and their 
role in stem cell populations. Evidence to date and the potential for translational 
application strongly supports further investigation into the role of Sox factors in tissue-
specific stem cell populations of the gastrointestinal tract.  
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INTRODUCTION 
 
The intestinal epithelium is one of the most proliferative tissues in the mammalian 
organism. The entire mono-layer of epithelium is replaced approximately every 7 days 
(12, 24), and this renewal process is driven by a pool of multipotent, self-renewing stem 
cells that are positioned between Paneth cells and also immediately above the Paneth cell 
compartment in the base of the crypt (8, 109). Typically, in the adult organism stem cells 
are thought to undergo an asymmetric division process that generates a larger pool of 
more rapidly dividing transit-amplifying populations (or progenitors) that are located 
higher up the crypt/villus axis towards the lumen (12, 24). Intrinsic and extrinsic 
signaling direct these progenitors to commit to one of four functionally distinct post-
mitotic cell types: the enterocyte (absorptive) (22), goblet cell (mucous producing) (20), 
enteroendocrine cell (hormone producing) (23), and Paneth cell (antimicrobial peptide 
producing) (21). With the exception of the Paneth cell population, the other three cell 
types migrate up the crypt-villus axis and are sloughed into the lumen at the villus tip. 
Paneth cells are born around cell position +5 (as numbered from the base of the crypt 
towards the lumen) and migrate down to the crypt base where they secrete antimicrobial 
peptides into the crypt lumen (21). Normal gut homeostasis is critically reliant on the 
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proper control of stem cell proliferation, division, and subsequent generation of the 
transit-amplifying progenitor pool. 
Significant progress towards identifying, isolating, and manipulating the IESC has 
been hindered by the lack of specific IESC biomarkers and suitable culturing techniques. 
Recently, a number of putative IESC biomarkers have been identified, but relatively few 
of these biomarkers have been tested to confirm that cells expressing these biomarkers 
pass the test of multipotency and self-renewal, the two functional characteristics that 
define a stem cell. Three studies have employed Cre-recombinase mediated genetic 
lineage tracing technology, currently the most rigorous method to assess multipotency in 
vivo, to demonstrate that the biomarkers, Lgr5, Bmi1, and CD133/prominin1 are 
expressed in cell populations that demonstrate multipotency and self-renewal capacity in 
the small intestine (8, 109, 121). The expression patterns of Lgr5, Bmi1, and 
CD133/prominin1 mark stem cell populations that are differentially positioned in distinct 
regions of the crypt. Lgr5 expression is restricted primarily to the crypt-based columnar 
cells (CBC) that are intercalated between the Paneth cells (8). Bmi1 also shows a highly 
restricted expression pattern that is primarily localized to the supra-Paneth cell region, the 
zone typically defined as cell position +4 (109). CD133/prominin1 exhibits a broad 
expression pattern encompassing the CBC positions through at least cell position +10 
(121). Although all three of these stem cell populations demonstrate multipotent capacity 
in vivo, it is unclear whether they have functionally equivalent roles in the homeostasis of 
the intestinal epithelial monolayer.  
We have recently shown that distinct levels of Sox9-expression mark putative 
IESCs based on enriched levels of Lgr5 mRNA in discrete cell populations (39). SOX9 is 
a transcription factor that not only marks stem/progenitor cells in various tissues, but it 
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also has an established role in maintaining the multipotent and proliferative capacity of 
stem/progenitor populations (88, 89). Using fluorescence activated cell sorting (FACS) of 
dissociated small intestine epithelium from a Sox9EGFP reporter gene mouse model, we 
demonstrated that ‘low’ levels of Sox9EGFP (termed Sox9EGFPlo) mark cells that are 
enriched for Lgr5 (39); moreover, we identified that ‘high’ levels of Sox9EGFP (termed 
Sox9EGFPhi) mark post-mitotic enteroendocrine cells (39). Expression of endogenous 
levels of Sox9 mRNA and SOX9 protein were consistent with the Sox9EGFPlo and 
Sox9EGFPhi levels validating that the Sox9EGFP reporter gene faithfully recapitulates 
expression patterns of endogenous Sox9 (39). Although formal inducible Cre-mediated 
genetic lineage tracing studies using Sox9 as a biomarker have not yet been conducted in 
an adult experimental model, Cre-mediated lineage tracing during embryonic gut 
development suggests that Sox9-expression marks multipotent IESCs at E17 (1). This 
embryonic lineage tracing study provides compelling evidence that Sox9-expression 
marks a population of IESCs in the embryo that may be conserved in the adult. 
Due to the CBC location and enriched Lgr5 expression in the Sox9EGFPlo population, we 
hypothesized that Sox9EGFPlo expression marks functional IESCs. To test this hypothesis 
we utilized a recently described novel in vitro assay that provides a culturing 
environment, which supports the generation of crypt-villus like structures from a single 
Lgr5-expressing intestinal epithelial stem cell (112). In this study we also characterize 
genetic signatures of small intestine epithelial stem/progenitor populations exhibiting 
different Sox9-expression levels, and explore the multipotent and self-renewal capacity of 
these different populations of Sox9-expressing crypt cells. In an attempt to identify a cell 
surface marker that can be used to enrich for multipotent IESCs without the requirement 
of a specialized fluorescent reporter gene animal model, we investigate the co-expression 
37 
pattern of Sox9EGFPlo and the Cluster-of-Differentiation marker, CD24, a cell surface 
marker that has been reported to be putative stem cell biomarker and is easily detected 
using widely available FACS antibodies (104, 145).  
 
MATERIALS AND METHODS 
 
Mice/Genotyping 
 The Sox9EGFP mouse line was originally generated as part of the GENSAT Brain 
Atlas Project (43) and contains genomic integration of a modified BAC (RP32-140D18) 
with ~75.5 kb upstream and ~151kb downstream sequence to Sox9. Frozen Sox9EGFP 
mouse embryos were obtained from the Mutant Mouse Regional Resource Center 
(University of California-Davis) and reconstituted by transfer into foster mice. All mice 
are on the outbred CD-1 strain and were maintained as heterozygotes on the CD-1 genetic 
background. Mice breed normally and live to adulthood with no overt phenotypes due to 
the transgene. At ~10 days post-natal, tail snips were viewed under an epi-fluorescent 
microscope fitted with filters for EGFP visualization. A high level of EGFP fluorescence 
compared to transgene negative control mice was scored as positive for the Sox9EGFP 
transgene.  
Tissue dissociation/FACS 
To isolate intestinal crypt cells for Fluorescence Activated Cell Sorting (FACS), 
small intestine epithelium was dissociated into single cells essentially as previously 
described (33) with the following modifications. For FACS experiments mouse intestines 
were flushed with cold phosphate-buffered saline (PBS), cut open lengthwise in 
approximately 10 cm long pieces, and immersed in PBS/30 mM 
ethylenediaminetetraacetic acid (EDTA)/1.5 mM dithiothreitol (DTT) over ice for 20 
minutes. The solution was disposed of and the tissue was shaken vigorously in fresh 
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PBS/30 mM EDTA for approximately 30 seconds before being incubated at 37°C for 10 
minutes. Intact tissue was discarded and dissociated crypts and villi were pelleted at 2500 
rpm for 5 minutes. The cells were washed twice with cold PBS, resuspended in Hank’s 
buffered saline solution (HBSS)/0.3U/mL dispase at 37°C and shaken approximately 
every 2 minutes for 10 minutes. Then, fetal bovine serum (FBS, 10%) and 100 µg 
DNaseI was added before the cells were passed through a 100 µm filter. Cells were 
pelleted at 2500 rpm for 5 minutes and resuspended in 4 mL HBSS with 10% FBS, then 
passed through a 70 µm filter and combined with an additional 100 µg DNaseI. 
Equivalent numbers of cells from three animals were combined and passed through a 30 
µm filter immediately prior to FACS.  
Sox9EGFP and CD24–expressing cells were isolated using a MoFlo XDP FACS 
machine (Dako/Cytomation, Carpinteria, CA). Cells were collected in ice cold Advanced 
DMEM/F12 supplemented with 10µM Y27632 (Sigma, Saint Louis, MO) and kept on ice 
throughout the sort. Forward-Side Scatter gating was used to exclude 99.8% of all dead 
cells and lymphocytes. Both Forward Scatter and Side Scatter height-width plots were 
used for doublet discrimination to maximize efficient single cell sorting. Sort gates for 
Sox9EGFP expression were defined by previous studies (39) with the inclusion of more 
precise parameters to include the Sox9EGFPsubLo population. Cells were sorted into medium 
described above. 
For CD24 or CD133 staining 1x107 cells were isolated as described above and 
were stained with 5µL rat anti-mouse CD24 preconjugated with Pacific Blue (BioLegend, 
San Diego, CA) or anti-mouse CD133 preconjugated with Allophycocyanin (APC) 
(BioLegend) in 2mL Advanced DMEM/F12 (Invitrogen, Carlsbad, CA) for 1 hour on ice.  
The cells were washed twice in Advanced DMEM/F12 prior to FACS. Gate decisions for 
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CD24 or CD133 positive cells were made based on comparison to Pacific Blue or APC 
conjugated isotype control stained cells. 
Tissue Culture 
Tissue culture methods were carried out essentially as previously described (112) 
with the following modifications. FACSorted cells were transferred to 2.0 mL conical 
tubes and pelleted at 4500 rpm for 5 minutes at 4°C before being resuspended at an 
approximate density of 2000 cells/50µL/well (24-well plate) in Matrigel (BD 
Biosciences, San Jose, CA) supplemented with 1µM JAGGED-1 peptide (AnaSpec, San 
Jose, CA), 50ng/mL EGF (R&D, Minneapolis, MN), 100ng/mL NOGGIN (Peprotech, 
Rocky Hill, NJ), and 1µg/mL R-SPONDIN1 (R&D). All mass per volume growth factor 
concentrations were calculated in respect to the 500µL final volume of media per well. 
To facilitate ease of observation, 50µL droplets of Matrigel/cell suspension were added 
per well to 24-well plates. After total polymerization, each formed droplet was overlaid 
with 500µL Advanced DMEM/F12 containing N2 supplement (Invitrogen), B27 
supplement minus vitamin A (Invitrogen), 10mM HEPES (Invitrogen), and 10µM 
Y27632 (Anoikis inhibitor). Growth factors were added every other day at the same 
initial concentrations, with the exception of R-SPONDIN1, the dosage of which was 
reduced to 500ng/mL for all time points following the initial plating. Media was replaced 
every four days. Y27632 was withdrawn at culture day four with the first media change 
and not included in any subsequent culture maintenance.  
For passaging experiments, organoids were isolated from Matrigel with a pipette 
and transferred to Advanced DMEM/F12 with 10µM Y27632 in 2.0mL conical tubes. 
Single cells were obtained by mechanical trituration of isolated organoids followed by 
incubation in 0.3U/mL Dispase (BD Biosciences) for 20 minutes at 37°C combined with 
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trituration every 5 minutes before media was collected and cells were plated again in 
Matrigel as described above. 
cDNA Preparation/Real-time PCR Analysis 
 cDNA from approximately 0.75-1.0 x 105 cells from each FACSorted population 
(Sox9EGFPneg, Sox9EGFPsubLo, Sox9EGFPlo, and Sox9EGFPhi) was made using RNAqueous 
Micro Kit (Ambion, Austin, TX) according to the manufacturer’s protocols. Time 
between the death of the mouse to RNA extraction was kept to 3.5 to 4 hours to ensure 
the highest quality of RNA. Real-time PCR was conducted for each sample in triplicate 
on approximately 1/20,000 of the total amount of cDNA generated. Taqman probes (18S, 
HS99999901;  Ascl2 Mm01268891_g1; Atoh1, Mm00476035_s1; CD133 
Mm00477115_m1; CD24 Mm00782538_sH; ChgA Mm00514341_m1; cMyc 
Mm00487803_m1; CyclinD1 Mm03053889_s1; S100a4 (FSP), Mm00803371_m1; Hes1, 
Mm00468601_m1; Lactase Mm01285112_m1; Lgr5, Mm00438890_m1; Notch1, 
Mm00435245_m1; Olfm4 Mm01320260_m1; Smooth Muscle Actin (SMA), 
Mm01546133_m1; Sox9, Mm00448840_m1; Substance P, Mm00436880_m1) for each 
gene were obtained from Applied Biosystems (Pleasanton, CA) and used in reactions 
according to the manufacturer’s protocol. 18S ribosomal RNA was amplified and used as 
the internal control gene for sample comparison. Delta CT values were calculated to 
obtain fold-changes for sample comparison (95). 
Immunostaining/Microscopy 
 For tissue preparation, small intestines were dissected from adult Sox9EGFP mice 
(>8 weeks of age) and luminal contents were flushed-out with PBS followed immediately 
by a single flush with freshly made 4% paraformaldehyde (PFA). The intestine was 
opened along the duodenal-ileal axis, and fixed for an additional 14-18 hours at 4°C. The 
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tissues were then prepared for cryosectioning by immersion in 30% sucrose solution for 
at least 24 hours at 4°C. Tissues were then embedded in Optimal Cutting Temperature 
(OCT) medium and frozen on dry ice. The OCT blocks were stored at -80°C until 
cryosectioning. Thin sections (8-10µm) were cut on a cryostat and placed on positively 
charged microscope slides for staining and microscopy. This tissue preparation technique 
is critical for preserving the EGFP fluorescence.  
 Organoids were prepared for immunostaining by aspirating culture media from 
Matrigel cultures and fixing entire contents of each well with 4% PFA for 14-18 hours at 
4°C. Following fix, PFA was removed and replaced with 30% sucrose solution for at 
least 24 hours at 4°C. Organoids were then removed from Matrigel with a micropipette, 
embedded in OCT medium, and frozen on dry ice. The OCT blocks were stored at -80°C 
until cryosectioning. Thin serial sections (8-10µm) were cut on a cryostat and placed on 
positively charged microscope slides for staining and microscopy.    
 For immunostaining, the sections were washed twice in PBS to remove OCT, 
followed by incubation in blocking medium (5% normal goat or donkey serum (NGS or 
NDS)), in PBS-0.3% Triton-X100) for at least 30 minutes at room temperature (21-
25°C). Primary antibodies were applied to the tissue sections in antibody staining 
solution (1% NGS, in PBS-0.3% Triton-X100). Dilutions were as follows: 
αCD326/EpCAM (rat, 1:1000, BioLegend, 118211), aLysozyme (rabbit, 1:1000, 
Diagnostics Biosystems, Pleasanton, CA, RP 028), aMucin2 (rabbit; 1:100, Santa Cruz 
Biotechnology, Santa Cruz, CA, sc-15334), aSOX9 (rabbit, 1:1000, Chemicon, 
Temecula, CA, AB5535), aSubstance-P (rat; 1:500, Chemicon, MAB356), aSucrase 
Isomaltase (goat; 1:100, Santa Cruz Biotechnology, sc-27603). All secondary antibodies 
(aRabbit-Cy3, Sigma, Saint Louis, MO, C2306; aRabbit-Alexafluor 488, Molecular 
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Probes, Eugene, OR, Z-25302; aRat-Alexafluor 555, Molecular Probes, Z-25305; aGoat-
Cy3) were used at a 1:500 dilution in staining buffer. Nuclei were stained with Draq5 
(1:10,000, Biostatus, Ltd, San Diego, CA, BOS-889-001). Background staining was 
negligible as determined by non-specific IgG staining. 
 Day to day development of organoids was tracked using light microscopy. 
Defects in culture plate plastic were utilized as “landmarks” to facilitate consistent 
observation of developing organoids. Epifluorescence images were captured on an 
Olympus IX70 fitted with an Olympus digital camera. Objective lenses used were 20X 
and 40X with numerical apertures of 0.55 and 1.40 respectively. All confocal images 
represent 1.0 µm optical sections unless otherwise noted. Objective lenses for the 
confocal images were 40X – 63X with a numerical aperture = 0.1.  
 
RESULTS 
 
A cell population enriched for IESC biomarkers can be distinguished from progenitor 
cells based on Sox9EGFP levels 
 
 Sox9 is expressed at different levels in cells localized to the bottom region of the 
crypts (39, 140). Our previous study demonstrated that high levels of Sox9 marked 
mature enteroendocrine cells, and that lower levels of Sox9 marked a cell population that 
was enriched for the experimentally validated biomarker, Lgr5. Our initial report on Sox9 
expression in the small intestine crypts did not describe a third population that can be 
visualized by immunostaining for endogenous SOX9 and also by Sox9EGFP transgene 
expression (Figure 1A). Distinct Sox9EGFPsubLo cells are observed by immunostaining and 
transgene expression in all crypts of the small intestine (data not shown). We have 
defined these cells as ‘sub-low’ (subLo) expressing cells based on low but detectable 
levels of SOX9 and Sox9EGFP, and show that these cells localize to the transit-amplifying 
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progenitor cell population (Figure 1A and S1). Using the mouse model in which Sox9 
regulatory regions control expression levels of the EGFP reporter gene, we sought to 
define parameters that would allow specific separation and isolation of IESCs from 
progenitor populations. We reasoned that by further dividing low-expressing Sox9EGFP 
cells into two more precise categories: a) Sox9EGFPlo levels, and b) the lowest detectable 
levels of Sox9EGFP, termed Sox9EGFPsubLo, we would potentially enrich and separate 
Sox9EGFPlo-expressing IESCs from Sox9EGFPsubLo transit amplifying cells (Figure 1B). 
FACS cells based on Sox9EGFPneg, Sox9EGFPsubLo, Sox9EGFPlo, and Sox9EGFPhi sort 
parameters demonstrated efficient separation of the 4 populations of Sox9EGFP-expressing 
cells (Figure 1C). 
To determine the genetic profiles of each of these populations, we conducted real-
time semi-quantitative RT-PCR (sqRT-PCR) for ‘stemness’ and lineage specific genes. 
Sox9 mRNA levels were consistent with Sox9EGFP transgene levels, thus validating the 
Sox9EGFP-based FACSort (Figure 2A). Sox9EGFPlo cells show enriched expression for the 
validated IESC biomarker, Lgr5, as well as the two putative IESC biomarkers, Olfm4 and 
Ascl2, which have been shown to co-localize with the Lgr5 CBC population (139, 140) 
(Figure 2A). Two hallmarks of stem/progenitor cell maintenance are active Wnt/ß-
catenin (71) and Notch-pathway signaling (103, 141). To determine whether these two 
pathways were active in Sox9EGFPlo cells we assessed the expression levels of Wnt-target 
genes, c-Myc and CyclinD1, and also Notch1 and its downstream target, Hes1 (Figure 
2B). Our result show increased expression of c-Myc/CyclinD1 and Notch1/Hes1 in the 
Sox9EGFPlo and Sox9EGFPsubLo populations demonstrating intact signaling of these two 
pathways in both populations. Interestingly, Sox9EGFPsubLo cells were distinguishable from 
Sox9EGFPlo cells by marked up-regulation of Atoh1 (Math1) (Figure 2C). Atoh1-
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expression is an indicator of early stem cell differentiation into secretory lineages (156), 
consistent with a ‘progenitor cell’ nature of the Sox9EGFPsubLo population. Analysis of the 
lineage specific genes, Chromogranin A and Substance P, show that the Sox9EGFPhi sort 
parameters enrich for enteroendocrine cells. Increased Lactase expression in the 
Sox9EGFPneg population indicates this population is enriched for differentiated enterocytes 
(Figure 2C). Together these results demonstrate that FACS based on Sox9EGFP-expression 
levels allows for the efficient isolation and enrichment of distinct cell populations of the 
small intestine epithelium, specifically, Sox9EGFPhi enteroendocrine cells, Sox9EGFPlo 
IESCs, Sox9EGFPsubLo progenitors/transit amplifying cells, and Sox9EGFPneg differentiated 
enterocytes. 
Single Sox9EGFPlo intestinal epithelial stem cells generate organoids and differentiate 
into Paneth cells, enteroendocrine cells, goblet cells, and enterocytes 
 
Sox9EGFPlo cells show enriched expression for established markers of multipotent 
IESCs, but we wished to establish if these cells possess functional multipotent 
characteristics of IESCs. To assess whether Sox9EGFPlo cells have the capacity to give rise 
to crypt/villus-like structures containing all four post-mitotic epithelial cell populations of 
the small intestine, we dissociated small intestine epithelium from Sox9EGFP mice, 
isolated Sox9EGFPlo cells by FACS, and plated cells into a 3-dimensional (3-D) culture 
system that has been recently described (112). A single cell was identified and followed 
using bright field and fluorescence microscopy from 24-hours post-plating to 19-days 
post plating to assess growth rate and morphological changes (Figure 3 and S5). Twenty-
four hours post-plating, the single cells undergo cell division generating micro-colonies, 
which are composed of cells that maintain Sox9EGFP expression (Figure 3B). By 48-hours 
post-plating the micro-colony develops a pseudo-lumen that is fully developed by 6-days 
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post-plating. The pseudo-lumen contains dead/apoptotic cells, which was indicated by 
punctate, fractured nuclear staining (data not shown), and high levels of autofluorescence. 
Clear segregation of cell types expressing distinct levels of Sox9EGFP was observed by 
day 9 and was coincident with the initial formation of crypt buds, which were fully 
developed by day 12-16 (Figure 3C). Two gross morphologies of ‘organoids’ (112) were 
observed, one defined by an ‘open’ configuration where the dead/apoptotic cells were 
expelled into the Matrigel, and a second defined by a ‘closed’ confirmation where the 
dead/apoptotic cells were expelled into a central luminal cavity (Figure 3C). Organoids 
were allowed to grow in culture until they either became disorganized or grew large 
enough to come into contact with the bottom of the plate, which usually occurred 
between 16 and 20 days in culture. At this point, the organoids were dissociated by 
mechanical trituration and re-plated into the 3-D culture system. The re-plated cells were 
able to give rise to multiple organoids for multiple passages (at least 6 to date) indicating 
the self-renewal capacity of the IESCs within the original organoid. Single Sox9EGFPlo 
cells were able to give rise to organoids with a well-defined pseudo-lumen (day 2-6) at an 
average incidence of 5% (5 organoids/100 FACSorted Sox9EGFPlo cells plated), however, 
fully-formed organoids with well-defined crypt units that were present at day 12-16 were 
more rare and were present at an average incidence of 1%. It is important to note that 
upon culturing Sox9EGFPneg, Sox9EGFPsubLo, and Sox9EGFPhi cells mature organoids never 
formed, further validating that Sox9EGFPlo sort parameters were effectively isolating the 
multipotent, self-renewing IESC population. 
To determine whether Sox9EGFPlo cells in the organoid where able to give rise to 
the four post-mitotic differentiated cells types of the small intestine epithelium, we 
sectioned a single organoid and used immunostaining to identify the cell lineages 
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represented. The data indicate cells in the organoid are epithelial in nature as 
demonstrated by positive immunostaining with Epithelial Cell Adhesion Molecule 
(EpCAM; Figure 4A).  The three secretory lineages were represented and identified by 
immunostaining for Lysozyme (Paneth cell; Figure 4B); Substance P (Enteroendocrine; 
Figure 4C); and Mucin2 (Goblet; Figure 4D). An interesting observation was that high 
levels of Mucin2 were present in the pseudo-lumen, which is physiologically consistent 
with normal gut function, and furthermore indicates cellular polarity. Enterocytes were 
identified by immunostaining for the brush-border enzyme, Sucrase Isomaltase (SIM) 
(Figure 4E). These data indicate that single Sox9EGFPlo IESCs have the capacity to 
function as multipotent IESCs in culture.  
 One pressing question is whether contaminating mesenchymal cells, which may 
be attached to a Sox9EGFPlo IESCs and therefore undetectable using FACS doublet-
discrimination parameters, are providing instructive signals and mitogens to the 
organoids. To address this question, we visually assessed post-sort cells using 
fluorescence microscopy and never identified a cell aggregate containing a non-Sox9EGFP-
expressing cell. A more objective approach to answer this question was to section an 
entire organoid and immunostain for biomarkers of fibroblasts (Fibroblast Specific 
Protein-S100a4) and myofibroblasts (smooth muscle actin – SMA), the major cell types 
that have been proposed to support the stem cell niche and crypt formation in vivo (68). 
Although tissue sections of intact small intestine demonstrated robust immunostaining 
staining for fibroblast/myofibroblast markers, no staining was ever observed in 12-16 day 
old organoids indicating cells marked by SMA or S100a4 do not appear to be supporting 
in vitro growth of organoids (data not shown).  
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CD24 can be used to isolate and enrich for IESCs that form organoids in culture  
 
To date, no cell surface marker has been identified that can be used to FACS-
isolate normal IESCs. Although investigators have been searching for a single biomarker 
that exclusively marks stem cell populations, no one single gene has been demonstrated 
to possess this characteristic. Prevailing evidence suggests that pure stem cell populations 
may be isolated from a larger pool of heterogeneous cells by using a combination of cell 
surface biomarkers that produce a genetic signature for the stem cell. For example, 
Cluster-of-Differentiation (CD) markers are a class of cell surface proteins that have been 
used to successfully FACS-isolate multipotent stem cells from other epithelial tissues 
such as the brain, pancreas and mammary glands (3, 101, 104, 145). One common feature 
of all these epithelial stem cell populations is that CD24 is expressed on the cell surface 
and can be used in combination with FACS to enrich for stem cells from the 
heterogeneous cell isolates. CD24 is a short signal-transducing cell surface protein that 
was first characterized in B-lymphocytes (54, 65, 66) and has been since shown to be a 
ligand for P-SELECTIN, an adhesion molecule found on activated platelets and 
endothelial cells (107). The role of CD24 in the small intestine epithelium is currently not 
understood. 
To explore the possibility of using CD24 as potential enrichment factor for 
IESCs, we conducted gene expression analysis for CD24 using real-time semi-
quantitative RT-PCR (sqRT-PCR) on Sox9EGFPlo and Sox9EGFPsubLo FACSorted cells and 
compared their CD24 expression with CD24 expression in Sox9EGFPneg cells (Figure 5A). 
The data show there is a 5- to 7-fold increase in CD24 mRNA in Sox9EGFPsubLo and 
Sox9EGFPlo cells compared to Sox9EGFPneg cells (Figure 5A). Likewise, flowcytometric 
analysis demonstrates CD24 protein is expressed in >99% of Sox9EGFP positive cells 
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(Figure 5B). These data support the concept that CD24 is a potential candidate biomarker 
for isolating and enriching IESCs from non-transgenic tissue sources. 
CD24 is present on the surface of some non-IESC types; therefore, FACS gates 
must be clearly defined to specifically identify where the IESC population is located on a 
CD24/Forward-Scatter FACS histogram. Since organoids could only be generated from 
IESCs isolated using Sox9EGFPlo parameters, we reasoned that Sox9EGFPlo status could be 
used as a color-gating tool to identify where IESCs were located on a FACS histogram 
with only CD24 and forward-scatter as variables. Color gating is an algorithmic feature 
of flowcytometry software that allows a defined parameter (like EGFP expression status) 
to be mapped back onto cells on a FACS histogram that does not contain an EGFP 
variable. In other words, Sox9EGFPlo cells can be recognized on a CD24 vs. forward-
scatter histogram to reveal where the Sox9EGFPlo IESC population falls within CD24-
expressing cells. The significance of using this strategy is that defined sort parameters (or 
‘sort-gates’) can be specifically drawn to exclude the majority of CD24-expressing cells 
that do no contain IESCs. The IESC-specific CD24 gates can then be used as a standard 
to isolate and enrich for IESCs from any mouse intestinal epithelial tissue source, not just 
from specialized fluorescent reporter gene mice.  
Sox9EGFPlo intensities (Figure 6A-red events) that produced enrichment of IESCs 
and generation of organoids were used to define sort-gates on a bivariate histogram of 
CD24-stained intestinal epithelial cells from a Sox9EGFP mouse (Figure 6C-F, red-events). 
A bivariate EGFP/CD24 histogram indicated there were four discernable populations, 
which were used to define sort gates (CD24-high, medium, low, and negative) (Figure 
6B). Color-gating only the Sox9EGFPlo cells onto the CD24/FSC histogram shows that a 
majority (60%) of all Sox9EGFPlo cells fall into the CD24lo gate (Figure 6D, F; red events) 
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representing 19% of all cells within the CD24lo sort parameter (Figure 6F & 7A). 
CD24med and CD24hi gates contain significantly less Sox9EGFPlo cells, 9% and 4%, 
respectively. A significant number of Sox9EGFPlo cells (27%) fell in the CD24neg sort 
parameter, however, this represented only 0.5% of all cells within that gate indicating a 
de-enrichment of IESCs in the CD24neg population (Figure 6D, F & 7A).  
As proof-of-concept, the same color-gating strategy was used to determine 
whether CD133, a validated IESC marker by lineage tracing, would also be a candidate 
cell surface marker for the isolation of Sox9EGFPlo IESCs. CD133 has a broad expression 
pattern that encompasses the CBC cells up the crypt axis to the transit-amplifying cell 
zone (121). sqRT-PCR and flowcytometric analyses indicate that CD133 mRNA and 
protein are expressed in the Sox9EGFPsubLo and  Sox9EGFPlo populations (Figure S2). Color-
gating demonstrates that the Sox9EGFPlo population (94.8%) expresses CD133 on the 
surface, however, the CD133-APC fluorescence shift is too low to enable significant 
separation of the Sox9EGFPlo IESCs from CD133–negative cells (Figure S3). If the sort 
gates indicated on the CD133/FSC histogram were used to isolate Sox9EGFPlo IESCs, only 
10.7% of the cells would be Sox9EGFPlo cells representing approximately half the 
enrichment factor compared to using CD24 as a FACS marker.  
To identify which CD24 gate contained cells with functional IESC characteristics, 
we introduced the four cell populations (CD24 negative, high, medium and low) into 
organoid culture conditions. Organoids were generated only from CD24lo and CD24med 
populations at an incidence of 1:200 (CD24lo) and 1:1000 (CD24med) (Figure 7A, B). 
There was no overt difference in the morphology or growth between organoids derived 
from cells isolated from the CD24lo and CD24med gates. No organoids formed from 
CD24neg or CD24hi populations indicating the cells in these two populations do not have 
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stem cell capacity in culture conditions. Organoids derived from CD24lo and CD24med 
cells demonstrated multipotency (Figure S4) and have been able to be expanded in 
culture for at least 4 passages to date. 
 
DISCUSSION 
 
 In this study we report that Sox9EGFPlo-expression levels can be used to isolate 
intestinal epithelial stem cells (IESCs) that are functionally defined by their ability to 
form organoids in vitro, self-renew, and contain all four post-mitotic cell types of the 
small intestine epithelium. Additionally, we show that distinct levels of CD24 expression 
enrich for IESCs, and can be used to efficiently FACS and isolate IESCs from non-
transgenic intestinal tissue, providing to our knowledge the first reported cell surface 
marker that can be used to FACS isolate and enrich for IESCs with functional 
characteristics. 
Although we have previously reported two distinct levels of Sox9 expression in 
the small intestine epithelium (39), in this study we describe a third level of Sox9-
expression termed Sox9EGFPsubLo. Co-localization of Sox9EGFPsubLo cells with the transit-
amplifying zone of the crypt, FACS enrichment for genetic markers of dividing 
progenitor cells, and the lack of multipotent and self-renewal capacity of Sox9EGFPsubLo 
cells suggest that sub-low levels of Sox9 mark transit amplifying progenitors. Using 
Sox9EGFPsubLo expression status as a cell isolation parameter will facilitate future studies 
on the small intestine epithelial progenitor population.  
An emerging concept in the literature is that Sox-transcription factors function in 
a dose-dependent manner to affect competence, potency and proliferation of stem and 
progenitor cell populations (102, 115, 132). Results from this present study and our 
previous work indicate that high levels of Sox9 are associated with non-dividing cells, 
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and a decreasing gradient of Sox9 is associated with stem/progenitor populations with 
increased proliferative capacities (39). The control of proliferation by Sox9 is in part 
exerted through modulating Wnt/ß-catenin signaling (2, 10, 39). Sox9 has been reported 
to be a downstream target of Wnt-signaling and appears to function by suppressing Wnt-
signaling in a negative feedback loop mechanism (2, 10). High levels of transiently-
expressed SOX9 in a non-transformed intestinal epithelial cell line halt proliferation 
indicating that SOX9 influences expression of proliferation genes (39), however, the 
exact mechanism by which SOX9 exerts control of proliferation is not understood and 
warrants further investigation into downstream effector genes. The ability to specifically 
sort the more rapidly dividing transit amplifying progenitor cells from the slower dividing 
IESCs of the small intestine epithelium will facilitate these investigations. 
 The seminal study describing the culture conditions for supporting the 
development of IESCs in vitro reports that single Lgr5-expressing cells are capable of 
building crypt-villus structures without a mesenchymal niche (112). A fibroblastic cell 
component has traditionally been thought to be essential for crypt-villus development 
(67, 69, 99, 124); therefore it was interesting that stereotypical crypt-villus units could 
form in the absence of a supporting cellular niche. The 3-dimensional culture conditions 
that facilitate crypt-villus development in culture do however provide many critical 
components similar to those a mesenchymal cell might contribute to an IESC niche, 
including laminin enriched extra-cellular matrix (110), growth factors, and Wnt-agonists 
(112). Under culture conditions that mimic an in vivo IESC niche, Sox9EGFPlo- and CD24-
expressing IESCs do not appear to require instruction from a mesenchymal cell 
component in order to expand and build crypt-villus units in culture. Immunostaining for 
Smooth Muscle Actin (SMA) or Fibroblast Specific Protein (FSP) failed to demonstrate 
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positive staining in serial sections through Sox9EGFPlo IESC derived organoids (data not 
shown). To rule out the possibility that identification of a small population of 
fibroblasts/myofibroblasts was beyond the threshold of detection of the immunostaining 
technology, we conducted sqRT-PCR on RNA isolated from both isolated crypts and 
post-sorted Sox9EGFPlo cells. sqRT-PCR analysis also failed to detect SMA or FSP from 
either sample after 40 cycles of PCR indicating there is no detectable contamination of a 
fibroblastic cell in the FACSsorted cells (data not shown). These data provide strong 
evidence that generation of crypt-villus units derived from Sox9EGFPlo cells do not require 
a fibroblastic cell component. This is consistent with the proposal that in this 3-D culture 
system IESCs are able to set-up a crypt-villus axis by differential intrinsic responsiveness 
of intestinal epithelial cells to Wnt-signals rather than from extrinsic stimuli (112). 
To date, FACS single IESCs that express experimentally validated markers of 
IESCs has required a specialized transgenic reporter-gene mouse expressing a fluorescent 
protein (8, 39). A previously reported method for isolation of a putative IESC population 
from non-transgenic mice was via side population (SP) sorting (32). Although the SP 
faction was shown to be from the crypt base, and to be enriched for putative IESC 
markers (47), SP cells have not been demonstrated to be capable of either replication or 
differentiation. We report here that CD24 is a cell surface biomarker that can be used to 
FACS enrich for cells with functional IESC characteristics (multipotency and self-
renewal) and possess the ability to form crypt/villus-like units in vitro from a non-
transgenic mouse. Low CD24 expression has been used as a marker to FACS isolate stem 
cells from the pancreas, brain, and mammary tissue (3, 101, 104, 107, 145). The 
expression pattern of CD24 in the normal small intestine epithelium is unknown, 
however, there are reports that CD24 is associated with epithelial cells in colonic 
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adenocarcinomas (79, 105). When using CD24 as a FACS biomarker for IESCs, 
organoids only developed from cells isolated from CD24lo and CD24med gates with an 
incidence of 0.5% and 0.1% respectively. This represents 2- to 10-fold reduction in 
organoid formation when compared to using Sox9EGFPlo expression alone as the sort 
parameter.  
Recent lineage tracing studies in mice suggest that CD133-expression marks a 
sub-set of crypt cells that exhibit IESC characteristics (121). The use of CD133 as a cell 
surface marker for FACS enrichment of these IESCs was not tested. Our data suggest that 
CD133 is not an efficient cell surface marker for enrichment of murine IESCs with 
antibody reagents currently available (Figure S3). Co-staining with CD24 and CD133 
with the goal of identifying a sub-population of putative IESCs failed to produce a unique 
fluorescent signature that could be used to further FACS enrich Sox9EGFPlo IESCs (data 
not shown). Putative IESCs marked by low levels of Sox9EGFP did exhibit expression of 
CD133 mRNA and protein (Figure S2), however, flowcytometry indicated that CD133 
expression levels appeared to be below a threshold that would allow separation and 
enrichment by FACS (Figure S3). A low avidity of the antibody for CD133 is an 
alternative explanation that might explain the low fluorescent signature of CD133 in the 
flowcytometry histogram. Additional antibody reagents must be developed to test this 
hypothesis.  
Although the most rigorously validated biomarkers Lgr5, Bmi1, CD133 and Sox9 
appear to mark IESC populations, none of these markers have been shown to exclusively 
mark IESCs. For instance, like Sox9EGFP, Lgr5EGFP is expressed at high and low levels in 
the crypt-base. It was demonstrated that low-expressing Lgr5EGFP cells rarely gave rise to 
organoids (112) suggesting that Lgr5 also marks a non-IESC population. Furthermore, 
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only 6% of Lgr5EGFPhi cells demonstrated self-renewal and multipotent capacity (112). 
Although the low number Lgr5EGFPhi cells demonstrating functional IESC characteristics 
could be the result of isolation and culture conditions, it is also possible that not all of 
these cells are IESCs. We propose that a combinatorial approach using multiple genetic 
markers will provide a more robust genetic signature for the IESC and allow for a more 
pure population of IESCs to be isolated by FACS. As this study demonstrates, the 
Sox9EGFP mouse model combined with color-gating flow cytometry provides a powerful 
tool to screen both known and uncharacterized cell surface markers for their capacity to 
uniquely mark the IESC population. The ability to use CD24 as an IESC enrichment 
factor represents a new and transformative approach to IESC isolation, as well as to the 
study of IESC maintenance, expansion, and differentiation. 
 CHAPTER 4 
 
SIGNIFICANCE AND IMPLICATIONS FOR FUTURE WORK 
 
 
Defining a genetic signature for IESCs 
 Recent efforts in IESC biology have been intensely focused on the discovery of 
genetic markers that can be used to identify IESCs. In vivo lineage tracing was employed 
to validate Lgr5 as the first IESC marker, and these results were subsequently reinforced 
by data demonstrating that single Lgr5HIGH cells fulfill requirements for ‘stemness’ in 
vitro (8, 112). Our research identified Sox9 as a marker of IESCs, which was later 
independently confirmed by in vivo lineage tracing (41, 45). In addition to Lgr5 and 
Sox9, current genes confirmed as IESC markers by in vivo genetic lineage tracing are: 
CD133, Bmi1, and mTert (87, 109, 121). Olfm4, Ascl2, and Msi1 are also associated with 
IESCs based on expression patterns, but have not been confirmed with in vivo or in vitro 
assays (98, 139, 140). 
Despite the growing number of putative and confirmed IESC markers, it remains 
an important caveat that no gene identified to date can be classified as an exclusive 
marker. All exhibit expression patterns that encompass a number of cell types within the 
intestinal crypts. For example, evidence suggests that Lgr5 and Sox9  are not exclusive 
markers of IESCs. Sox9HIGH cells have been shown to co-localize with markers of 
enteroendocrine cells (39). Furthermore, only Sox9LOW- and Lgr5HIGH-expressing cells 
efficiently form cryptoids in vitro (45, 112).  
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 Evidence from other tissue types suggests that a combination of multiple markers 
may be necessary in order to accurately identify IESCs (3, 101, 104). For experimental 
purposes, the identification of IESCs using transgenic reporter animals and distinct gene 
expression levels, as demonstrated for Sox9 and Lgr5, is sufficient for downstream 
applications (45, 112). However, transgenic expression of reporter genes cannot be 
exploited toward the clinical application of stem cells, an important translational goal of 
stem cell biology. No studies to date have isolated human intestinal epithelial cells that 
have demonstrated characteristics of multipotency and self-renewal. Efforts to expand 
human intestinal epithelium are largely hampered by a lack of a genetic signature for 
human IESCs that allows for FACS isolation. The identification of cell-surface markers 
for IESCs in animal models could be applied toward overcoming the hurdle of IESC 
isolation from human tissue. Our work identifies CD24 as an enrichment factor for IESCs 
and suggests that this cell-surface marker might also be useful for isolation of human 
IESCs. As an alternative approach to identifying IESC-specific markers, genes associated 
with differentiated cell types could also facilitate IESC isolation through labeling and 
subsequent exclusion of these cells during FACS. A critical next step to enable FACS 
enrichment of IESCs is the identification of additional cell-surface markers that could be 
used in conjunction with CD24 to establish an IESC-specific genetic signature.   
In vitro approaches to the study of IESCs  
 
Until recently, the in vivo standard for assaying multipotency and self-renewal of 
putative stem cell populations in adult tissues, including the intestine, was genetic lineage 
tracing (125). However, this assay has obvious disadvantages in that it necessitates the 
57 
development of a transgenic mouse. Transgenic mouse development entails significant 
time and financial commitments, therefore an investigator must have confidence that a 
candidate gene will prove to be an IESC marker prior to deciding to pursue genetic 
lineage tracing.  
The techniques facilitating culture and differentiation of single IESCs, originally 
published by Sato, et al. and applied in our studies of Sox9, are significant in that they 
provide an additional in vitro standard by which to assay multipotency and self-renewal 
in putative IESC populations (45, 112). Since many putative IESC markers are expressed 
in multiple cell types within the intestinal crypts, the ability to isolate and assay cells 
expressing distinct levels of a gene – such as Sox9LOW and Lgr5HIGH – allows for a level 
of genetic specificity for IESC biomarkers beyond the limitations of in vivo lineage 
tracing. However, several caveats regarding the currently methodology of in vitro IESC 
assays stand to be considered. One major disadvantage of the conventional Matrigel 
IESC culture system is that it exposes isolated stem cells to
signaling from contaminating cell types as well as other IESCs. Culturing several 
hundred to several thousand cells in a single Matrigel patty prevents the development of a 
truly clonogenic cell population, and might in turn influence IESC behavior. Recent data 
has shown that co-culture of IESCs with Paneth cells greatly increases IESC survival, 
likely due to growth factors produced by Paneth cells (111). It remains to be shown 
whether other contaminating cells types can have positive or negative effects on normal 
IESC behavior in vitro.  
 Also disadvantageous to conventional Matrigel-based culturing of IESCs is that 
the cost of the system is prohibitive to high-throughput screening of growth factors and 
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pharmacologic compounds. The outcome of drug studies on IESCs in vitro may also be 
affected by contaminating cell types, as discussed above. A logical progression within the 
field is to establish a true clonogenic assay for the study of IESCs in vitro. Though no 
technology currently exists to facilitate this, collaborative efforts between stem cell 
biologists and biomedical engineers has led to the development of high-throughput assays 
for embryonic stem cells (6). Similar collaborations may prove advantageous to the 
intestinal stem cell field as well. To date, this in vitro system has only been used to assay 
isolated intestinal epithelial cells for stemness. Further technological advances might also 
adapt this assay to be amenable with genetic manipulation in vitro and provide the field 
with a very powerful tool for the study of molecular mechanisms in IESCs. 
Mechanistic roles for Sox in the small intestine 
 Though the identification of IESC biomarkers is a vital step toward understanding 
intestinal stem cell biology, the field must also be concerned with identifying the 
mechanisms by which IESCs are capable of maintaining stemness. Sox proteins are 
particularly attractive for the study of such molecular mechanisms both as transcription 
factors and as mediators of stemness and differentiation in tissues throughout the 
developing and adult organism (76).  
As discussed in previous chapters, Sox9 has a functional role in the intestinal 
epithelium as demonstrated by a phenotype resulting in hyperproliferation of IESCs and 
progenitor cells and loss of Paneth cells in pan-epithelial knockouts (10). However, 
further work is required to determine the changes in normal molecular characteristics of 
the epithelium that result in such a phenotype. Additionally, the broad expression pattern 
of Sox9 and its association with both differentiated and proliferating cell types suggests 
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that IESC-specific knockout is required in order to establish a definitive phenotype as 
relevant to stem cell biology (39, 45). The loss of Paneth cells in pan-epithelial Sox9-null 
mutants may contribute to the observed phenotype independent of Sox9 function in 
IESCs, as Paneth cells have recently been shown to be critical in maintaining the IESC 
niche (10, 111). Existing data suggest that future studies on the role of Sox9 in IESCs 
should focus on ablation of Sox9 in specific cell types within the intestinal epithelium, 
including IESC- and Paneth cell-specific knockouts. Data from cell-specific knockouts 
could begin to outline a precise signal transduction pathway through which Sox9 
intrinsically or extrinsically confers or controls stemness in IESCs. 
In addition to dissecting signaling mechanisms for Sox in the intestine, emerging 
data imply an epigenetic role for Sox factors in the maintanence of stemness. Recent 
studies have shown that stem cells contain unique chromatin modifications caused by the 
binding of transcription factors to cis-elements and have proposed that these epigenetic 
marks may facilitate stem cell potency (128). Specifically, Sox2 and Sox4 have been 
shown to create promoter-specific histone modifications associated with ES cells and 
early hematopoietic progenitors, respectively (78). This property of Sox factors may be of 
special interest in the intestinal epithelium, as Sox4 has previously been localized to the 
proliferative region in the crypts (119). To date, no extensive studies regarding the role of 
Sox4 in the intestinal epithelium have been carried out. However, elegant conditional and 
embryonic deletion of Sox4 and the other SoxC proteins, Sox11 and Sox12, has 
demonstrated that this subgroup of Sox factors is critical for stem cell survival in neural 
and mesenchymal tissues (11, 133). Given the central role for SoxC proteins in other 
stem cell populations and a known epigenetic role in pre-B cells, Sox4 may be an 
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attractive target gene in the study of IESCs, especially if this mechanism of conferring 
potency is preserved across different tissue types.  
It would also be of great interest to examine the functional relationship between 
Sox4 and Sox9. If compensatory for one another, deletion of either Sox4 or Sox9 might be 
expected to lead to an increase in expression of the compensatory factor. However, due to 
the structural differences between Sox4 and Sox9 (leading to their classification in distinct 
Sox subgroups), they may compete for the same DNA binding site while eliciting 
different effects (14). This second scenario could result in appreciable phenotypic 
consequences. That is, an increase in Sox4 interaction with orphaned Sox9 binding-sites 
could be responsible for the phenotypes resulting from the loss of Sox9. Interestingly, 
preliminary data generated in our lab has shown that Sox4 exhibits an expression pattern 
similar to Sox9 (data not shown). 
The work presented in this thesis establishes important models and reagents for 
the isolation of IESCs and mechanistic study of Sox factor contributions to stemness in 
the intestinal epithelium. Future studies will utilize novel conditional and temporal 
knockout animals to delineate phenotypes resulting from deletion of Sox4 and Sox9 in the 
intestinal epithelium as well as in specific cell types. A greater understanding of Sox-
mediated regulation of stemness could provide the basic biological knowledge necessary 
to exploit tissue-specific stem cells for the treatment of injury, degenerative disease, and 
cancer. 
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Table 1. Sox expression in embryonic and adult gastrointestinal (epithelium) tissue. 
 
 Expression  
Gene Embryonic Adult Reference 
Sox2 Foregut endoderm Stomach, esophagus (102, 131, 152) 
Sox3 Posterior foregut ND (152) 
Sox4 Pancreas Pancreatic islets, intestine (80, 119, 150) 
Sox5 Pancreas ND (80, 150) 
Sox6  Pancreatic islets (57) 
Sox7 Pancreas Esophagus, stomach, jejunum, 
ileum, ascending colon 
(80, 150) 
Sox8 Pancreas ND (80, 150) 
Sox9 Pancreas, pancreatic epithelial cords, 
primitive intrahepatic bile duct 
structures 
Pancreatic islets, intestine, colon, 
intrahepatic bile ducts 
(7, 10, 13, 39, 45, 80, 115, 116, 
150) 
Sox10 Pancreas ND (80, 150) 
Sox11 Pancreas ND (80, 150) 
Sox12 Pancreas Pancreatic islets (80, 150) 
Sox13 Pancreas, liver Pancreatic islets (80, 150) 
Sox15 Pancreas ND (80, 150) 
Sox17 Pancreas, biliary primordium Esophagus, stomach, intestine, colon (64, 80, 119, 123, 136) 
Sox18 Pancreas, liver Stomach, intestine, colon, liver, 
pancreas 
(80, 106)   
Sox30 Pancreas ND (80) 
 62 
Table 2. Sox expression in gastrointestinal pathology and disease. 
 	   	  
Gene Pathology Reference 
Sox2 Pancreatic intraepithelial neoplasia (up), intestinal metaplasia (down), gastric cancer (down), 
traceoesophageal fistula (down), ampulla of vater adenocarcinoma, Barrett’s esophagus 
(down), esophageal squamous cell carcinoma (up) 
 
(77, 92, 100, 102, 
135) 
Sox4 Colon cancer (up) (119) 
Sox6 Obesity-related insulin resistance (down) (57) 
Sox7 Gastric cancer (up, some cases), colon cancer (down, some cases) 
 
(63) 
Sox9 Colon cancer, gastric cancer (up) (13, 158) 
Sox13 Diabetes autoantigen, primary biliary cirrhosis autoantigen 
 
(38, 62) 
Sox17 Colon cancer (down) (119) 
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Table 3. Sox expression in cell lines derived from gastrointestinal tissue. 
 
Gene Cell line Reference 
Sox2 MKN45Hu, Stomach, TGBC11TKBHu, Stomach, KATOIIIHu, Stomach, LoVoHu, Colon, CaRIHu, Colon, 
Az521Hu, Stomach, Hep-12Hu, Liver 
 
(77, 92, 131, 155) 
Sox7 BxPC3Hu, Pancreas, PSN1Hu, Pancreas, Hs766THu, Pancreas, MKN45Hu, Stomach, TE2Hu, Esophagus, 
TE3Hu, Esophagus, TE4Hu, Esophagus, TE5 Hu, Esophagus, TE7 Hu, Esophagus, TE8 Hu, Esophagus, TE11 Hu, 
Esophagus, TE12 Hu, Esophagus, TE13 Hu, Esophagus 
 
(63) 
Sox9 HT29Cl.16EHu, Colon, LS174THu, Colon, DLD1Hu, Colon, HTC116Hu, Colon, SW480Hu, Colon, 
TC7Hu, Colon 
 
(13) 
Sox17 SW480Hu, Colon (64) 
Sox18 SW480Hu, Colon, TMK1Hu, Stomach, MKN45Hu, Stomach, PANC1Hu, Pancreas, BxPC3Hu, Pancreas, 
AsPC1Hu, Pancreas, PSN1Hu, Pancreas, Hs700THu, Pancreas, Hs766THu, Pancreas, MIA PaCa2Hu, Pancreas 
 
(106) 
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Figure 1. Sox9EGFP is expressed at 3 different levels in the small intestinal 
epithelium. Sox9EGFP is expressed at 3 different levels in the small intestinal 
epithelium. A: Sox9EGFP is expressed at variable levels, “HI,” “LO,” and “subLO,” in 
the crypts of the small intestine. HI levels are associated with postmitotic enteroendocrine 
cells, LO levels are associated with crypt-base columnar cells, “subLO” levels are 
associated with the transit-amplifying region of the crypt, and NEG levels are Sox9EGFP 
negative. Images represent 1,260X original magnification. B: flow cytometric analysis 
indicates distinct Sox9EGFP expression levels. Gate parameters used to sort each 
population are indicated above each region of the histogram. C: postsort analysis 
indicates that single Sox9EGFP-expressing cells have been isolated based on enhanced 
green fluorescent protein (EGFP) status. Images represent 200X original magnification. 
The image exposures for Sox9EGFPneg and Sox9EGFsubLo panels were doubled to 
produce images that would allow visualization of EGFP expression in these 2 
populations. 
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Figure 2. Sox9EGFP populations are reproducibly separated by FACS. A: Three separate FACS experiments performed on three 
different animals were analyzed to demonstrate that gating protocols for isolating Sox9EGFPsubLo, Sox9EGFPlo, and Sox9EGFPhi 
are reproducible based on histograms analyzing EGFP fluorescence. B: Numerical analysis of these data shows that the percent of 
sorted cells falling in each gate is consistent between experiments, demonstrating reproducibility in the separation of Sox9EGFP 
populations. Cut-off of the events on the right side of the histogram is due to gating parameters to exclude potential doublets. 
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Figure 3. Gene expression analysis demonstrates isolation and enrichment of intestinal epithelial stem cells (IESCs), 
progenitors, and enteroendocrine cells by use of fluorescence-activated cell sorting (FACS). Semiquantitative RT-PCR conducted 
on FACSed NEG, subLO, LO, and HI cells demonstrates enrichment of IESC stem cell biomarkers in the LO populations A: active 
Wnt/β-catenin and Notch1 signaling in subLO and LO populations B: and enrichment of committed secretory progenitors in the 
subLO population and enteroendocrine cells in the HI population. C: Elevated lactase expression in the NEG population indicates this 
population is enriched for enterocytes. All data points represent means ± SE from 3 independent experiments; statistical analysis was 
by ANOVA and post hoc 2 sample t-tests were then performed. A P value < 0.05 is considered statistically significant. Different 
letters above each bar represent data points that are statistically different from each other. 
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Figure 4. Single Sox9EGFPlo cells form complex organoids in vitro. A: single cells develop 
into large aggregates with crypt and villus-like structures over 7–10 days. The central 
pseudolumens of the single-cell-derived organoids expel apoptotic cells resulting from the 
sloughing of terminally differentiated epithelial cells. Arrows mark defects in culture plastic used 
as “landmarks” to track individual cells through early developmental phases into formed 
organoids. At day 9 the organoid grew large enough to obscure the tracking defects; therefore, 
additional tracking marks were identified (white arrows). B: epifluorescent images of organoids 
depicted in A. Note that the green pseudolumen is nonspecific autofluorescence and not EGFP 
fluorescence. Differential Sox9EGFP expression patterning remains evident throughout 
expansion in vitro. C: organoids form both open and closed morphologies, based on 
developmental positioning of the apoptotic pseudolumen. Apoptotic cells slough openly into 
Matrigel in the “open” morphology and are seen as a dense, dark region in the “closed” 
morphology. Ages of organoids are 12 days postsort (top) and 15 days postsort (bottom). 
Organoids are magnified 300X (top) and 200X (bottom). 
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Figure 5. Organoid survival is quantified by identification of unique morphology. A: Organoids were quantified in culture at 24-
hour intervals to determine survival rates. A & B: Following an initial drop, organoid survival at 120-144 hours leveled off at the 
same time crypt- like budding was observed. B: Organoids were scored as surviving if observed to have a characteristic morphology, 
marked by cellular organization in a round structure surrounding an apparently empty (24 hours) or apoptotic (120 hours) pseudo-
lumen. All data points represent means ± SE from three independent experiments; statistical analysis was by ANOVA and post-hoc 
two sample t-tests were then performed. A p-value < 0.05 is considered statistically significant. The different letters above each bar 
represent data points that are statistically different from each other. 
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Figure 6. Sox9EGFPlo cells are capable of differentiation into all postmitotic cell 
types associated with the intestinal epithelium. A: epithelial cell adhesion molecule 
(EpCAM) staining indicates organoids cells are epithelial. B: lysozyme marks Paneth 
cells near the base of crypt-like structures. C: enteroendocrine cells are labeled with 
Substance P and also restricted to the base of crypt-like structures in the organoids. D: 
Mucin2 demonstrates the goblet cell phenotype in crypt-like structures. Secreted Mucin2 
in the pseudolumen suggests that goblet cells are correctly polarized. E: sucrase 
isolmaltase (SIM) labels the apical ends of enterocytes lining the pseudolumen in the 
organoids. White boxes in the far left images (100X original magnification) represent 
areas magnified in the center 2 columns (800X original magnification). White arrows 
point to representative cells. Associated expression patterns in vitro correlate with those 
observed in vivo (far right). The organoid represented was cultured for 12 days.
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Figure 7. Small intestine epithelial stem/progenitor cells express CD24 mRNA and protein. A: Semiquantitative RT-PCR (sqRT-
PCR) demonstrates that CD24 is expressed 5.5- to 7.2-fold higher in the subLO and LO cells compared with Sox9EGFP-negative 
cells. All data points represent means ± SE from 3 independent experiments; statistical analysis was by ANOVA, and post hoc 2-
sample t-tests were then performed. A P value <!0.05 is considered statistically significant. Different letters above each bar represent 
data points that are statistically different from each other. B: flow cytometric analysis indicates that nearly all Sox9EGFP-positive 
cells express CD24 protein. Left: Pacific blue-conjugated isotype antibody control. Right: CD24-Pacific blue conjugated antibody. 
Gray brackets in the histograms represent the FACS gating parameters. 
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Figure 8. Flow cytometric analysis shows that a majority Sox9EGFPlo cells fall 
within CD24lo expression pattern. A: Sox9EGFP expression of dissociated small 
intestine epithelial cells on a univariate EGFP histogram. Black brackets indicate gate 
parameters. Color gating (red) allows visualization of Sox9EGFPlo population in 
histograms A-F. B: Sox9EGFP/CD24 bivariate histogram used to define the 4 CD24 gate 
parameters [negative (NEG), low (LO), medium (MED), and high (HI)]. C and E: IgG 
control antibody indicates there is no significant nonspecific staining. D and F: !CD24-
PB (Pacific blue) antibody labels 73% of Sox9EGFPlo cells. D: percentages represent the 
number of Sox9EGFPlo-expressing cells in each gate. Mean percentage ± SE for each 
population are as follows: NEG, 1.67 ± 0.25%; LO, 25.63 ± 0.95%; MED, 12.23 ± 
1.48%; HI, 9.33 ± 0.91%. E and F: just Sox9EGFPlo cells color backgated onto the 
CD24/FSC histogram to highlight their distribution on the histogram. F: percentages 
represent the relative number of all Sox9EGFPlo cells in each gate. Mean percentage ± 
SE for each population are as follows: NEG, 50.7 ± 5.37%; LO, 42.47 ± 4.34%; MED, 
10.23 ±"1.16%; HI, 0.50 ± 0.00%. 
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Figure 9. CD24 can be used as a biomarker to isolate and enrich for single cells 
capable of producing sustainable, differentiated organoids. A: table representing the 
enrichment of putative IESCs by using CD24 expression levels as sort criterion. Percent 
Sox9EGFPlo cells/gate ± number of Sox9EGFPlo cells/total number of cells per gate. 
Fold enrichment, percent Sox9EGFPlo cells per gate/percent Sox9EGFPlo cells in all 
sorted cells. CD24lo sort parameters demonstrate the highest potential for enrichment of 
IESCs. There is a 25.1X enrichment for Sox9EGFPlo cells in the CD24lo sort parameters 
compared with ungated cells. Organoid generating IESCs can be isolated only with the 
CD24lo (5 organoids in every 1,000 cells) and CD24med (1 organoid in every 1,000 
cells) sort parameters. B: representative organoids derived from single CD24lo- 
expressing cells (left, day 9; right, day 13). 
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Figure 10. Small intestine epithelial stem/progenitor cells express CD133 mRNA and protein – A: sqRT-PCR demonstrates 
CD133 is expressed 4.4-fold and 3.1-fold higher in the ‘subLO’ and ‘LO’ cells respectively when compared to Sox9EGFP negative 
cells. All data points represent means ± S.E.M. from three independent experiments; statistical analysis was by ANOVA and post-hoc 
two sample t-tests were then performed. A p-value < 0.05 is considered statistically significant. The different letters above each bar 
represent data points that are statistically different from each other. B: Flowcytometric analysis indicates that most Sox9EGFP-
positive cells (94.8%) express CD133 protein. (left panel) APC-conjugated isotype antibody control. αCD133-APC conjugated 
antibody. (right panel) Grey brackets in the histograms represent the FACS gating parameters. 
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Figure 11. Using CD133 as an IESC FACS-enrichment marker is less efficient than 
CD24 – A: Sox9EGFP expression of dissociated small intestine epithelial cells on a 
univariate EGFP histogram. Black brackets indicate gate parameters. Color gating (red) 
allows visualization of Sox9EGFPlo population in histograms A-E. B and D: IgG control 
antibody indicates there is no significant non- specific staining. C and E: αCD133-APC 
antibody labels 94.8% of Sox9EGFPlo cells. D & E: Represent just Sox9EGFPlo cells 
color back-gated onto the CD133/FSC histogram to highlight their distribution on the 
histogram. E: Percentages represent the relative number of all Sox9EGFPlo cells in each 
gate. C & E: Note that although 94.8% of Sox9EGFPlo cells express CD133, the shift of 
the Sox9EGFPlo population on the CD133 axis is too small to sufficiently separate the 
Sox9EGFPlo cells away from non-Sox9EGFPlo cells. The upper-gates in each histogram 
represent the region of CD133-expressing cells that fall above the isotype control 
negative population. The lower-gates in each histogram represent the region of CD133-
expressing Sox9EGFPlo cells that fall above the isotype control negative population. 
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Figure 12. CD24-expressing IESCs are multipotent – 14 day organoids derived from 
CD24-FACSed IESCs were assessed for the presence of the four differentiated cells 
lineages of the small intestine epithelium by immunostaining. A: Paneth cells are marked 
by Lysozyme expression (red). B: Enteroendocrine cells are marked by Substance P (red). 
C: Goblet cells are marked by Mucin2 staining (red). D: Absorptive enterocytes are 
marked by the brush border enzyme Sucrase Isomaltase (SIM – red). All images are 
1260X original magnification. 
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